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ABSTRACT
Neuroinflammation  is  a  key  component  of  Parkinson’s  disease  (PD)  neuropathology.  Skewed
microglia  activation  with  pro-inflammatory  prevailing  over  anti-inflammatory  phenotypes  may
contribute  to  neurotoxicity  via  the  production  of  cytokines  and  neurotoxic  species.  Therefore,
microglia  polarization  has  been  proposed  as  a  target  for  neuroprotection.  The  peroxisome
proliferator-activated receptor gamma (PPARγ) is expressed in microglia and peripheral immune
cells,  where  it  is  involved  in  macrophages  polarization and  in  the  control  of  inflammatory
responses, by modulating gene transcription. Several studies have shown that PPARγ agonists are
neuroprotective in experimental PD models in rodents and primates. however safety concerns have
been raised about PPARγ agonists thiazolidinediones (TZD) currently available, prompting for the
development of non-TZD compounds. 
Aim of this study was to characterize a novel PPARγ agonist non TZD, MDG548, for its potential
neuroprotective  effect  in  PD  models  and  its  immunomodulatory  activity  as  the  underlying
mechanism of neuroprotection. The neuroprotective activity of MDG548 was assessed in vivo in the
subacute MPTP model  and in  the chronic MPTP/probenecid (MPTPp) model  of PD. MDG548
activity  on  microglia  activation  and  phenotype  was  investigated  in  the  substantia  nigra  pars
compacta (SNc) via  the evaluation of  pro-  (TNF-α and iNOS) and anti-inflammatory (CD206)
molecules, with fluorescent immunohistochemistry. Moreover, cultured murine microglia MMGT12
were treated with MDG548 in association with the inflammagen LPS, pro- and anti-inflammatory
molecules  were measured  in  the  medium by ELISA assay and phagocytosis  was  evaluated  by
fluorescent immunohistochemistry for CD68. 
MDG548 arrested dopaminergic cells degeneration in the SNc in both the subacute MPTP and the
chronic  MPTPp  models  of  PD,  and  reverted  MPTPp-induced  motor  impairment.  Moreover,
MDG548 reduced microglia  activation,  iNOS and TNF-α production,  while  induced CD206 in
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microglia.  In  cultured  unstimulated  microglia,  LPS  increased  TNF-α production  and  CD68
expression,  while  decreased  CD206  expression.  MDG548  reverted  LPS  effect  on  TNF-α  and
CD206 restoring physiological levels, while strongly increased CD68 expression.
Results suggest that the PPARγ agonist MDG548 is neuroprotective in experimental models of PD.
MDG548  targets  microglia  polarization  by  correcting  the  imbalance  between  pro-  over  anti-
inflammatory molecules, offering a novel immunomodulatory approach to neuroprotection.
4
TABLE OF CONTENTS
Acronyms and abbreviations 1
Introduction 4
                                                                                                                
1. Parkinson's disease 4
1.1 History and epidemiology 4
1.2 PD symptomatology: motor and non-motor deficits 4
1.2.1 Motor symptoms 5
1.2.2 Non-motor symptoms 5
1.3 Histological and biochemical hallmarks of PD 7
1.4 Etiology 10
1.4.1 Environmental factors 10
1.4.2 Genetic factors 11
1.5 Pathogenesis 12
1.5.1 Dopamine metabolism 13
1.5.2 Mitochondrial dysfunction 13 
1.5.3 Abnormal protein aggregation: role of α-synuclein 14
2. Neuroinflammation 16
2.1 Microglia and neuroinflammation 16
2.1.1 Microglial cells: role in the healthy brain 16
2.1.2 Activated microglia display morphological and phenotypical changes 19
2.1.3 Microgliosis and microglia phenotypes in PD 21
3. Animal models of Parkinson's Disease 24
3.1 MPTP model 25
3.1.1 MPTP: finding and history 25
3.1.2 Mechanism of neurotoxicity 26
3.1.3 MPTP acute and subacute protocols 27
3.1.4 MPTP chronic protocol 27
4.  Peroxisome proliferator-activated receptor (PPAR) 29
4.1 PPARγ 29
5.  MDG548 32
Aim of the study 34
Materials and Methods 36
1. Drugs 36
2. In vitro tests 36
2.1 Primary culture of cerebral cortical neurons 36
2.2 CalceinAM cell viability assay 37
2.3 PrestoBlue cell viability assay 37
2.4 Neutral red uptake assay for cell viability/cytotoxicity 38
2.5 HEK-Blue NF-kB reporter assay 39
2.6 Culture of murine microglial cell and in vitro immunohistochemistry 39
2.7 Cytokines quantification by ELISA assay 41
3. In vivo methods 41
3.1 Subacute treatment 41
3.2 Chronic treatment 42
3.3 Beam traverse test 42
3.4 Immunohistochemistry/Immunofluorescence 43
3.5 Stereological counting of TH-immunoreactive and Nissl-stained neurons 44
3.6 CD11b analysis 45
3.7 iNOS analysis 45
3.8 CD11b/TNF-α and CD11b/CD206 colocalization analysis 45
4. Statistics 46
Results 47
1. Neuroprotective potential and immunomodulatory properties of MDG548 in cultured cells 47
Determination of MDG548 cytotoxicity against rat cortical neurons 47
MDG548 exposure protected rat cortical neurons from H2O2-mediated injury 48
MDG548 protected PC12 dopaminergic-like cells against MPP+-induced toxicity 51
MDG548 inhibited LPS-induced activation of NF-kB 52
MDG548 altered microglia phenotype in LPS-stimulated MMGT12 54
MDG548 affected phagocytosis in MMGT12 cells 56
2. Neuroprotective properties of MDG548 in MPTP models in mice 57
MDG548 reverted MPTPp-induced motor impairment 57
MDG548 prevented MPTP-induced degeneration of the SNc 
in the subacute MPTP protocol 58
MDG548 arrested MPTP-induced degeneration of the SNc 
in the chronic MPTPp protocol 59
3. Modulation of the neuroinflammatory response by MDG548 61
Changes in microglia activation and iNOS induction in the subacute 
MPTP protocol 61
Changes in microglia activation and cytokines production in 
the chronic MPTPp protocol 64
Discussion 68
1. MDG548 is neuroprotective in PD models 68
1.1 In vitro studies 68
1.2 In vivo treatments 69
2. MDG548 displays immunomodulatory effects in microglia and in PD models in vivo 72
2.1 Immunomodulatory effects in cultured microglia 72
2.2 Immunomodulatory effects in in vivo treatments 76
Conclusions 78
References 79

ACRONYMS AND ABBREVIATIONS
6-OHDA 6-hydroxydopamine
AADC aromatic amino acid decarboxylase
AD Alzheimer's disease 
ALS amyotrophic lateral sclerosis
AP-1 activator protein 1 
ATP adenosine triphosphate
CD11b integrin alpha M
CD206 mannose receptor
CNS central nervous system
COMT catechol ortho-methyltransferase 
CSF cerebrospinal fluid  
DA dopamine
DAT membrane dopamine transporter 
DOPAC 3, 4-dihydroxyphenylacetic acid
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IL interleukin
iNOS inducible nitric oxide synthase
L-DOPA l-dihydroxyphenylanaline 
LPS lipopolysaccharide
LRRK2 Leucine-rich repeat kinase-2 
MAO monoamine oxidase 
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MHC major histocompatibility complex
MPDP+ 1-methyl-4-phenyl-3,4,-dihydropyridine 
MPP+ 1-methyl-4-phenylpyridium ion 
MPPP 1-methyl-4-phenyl-4-propionoxy- piperidine 
MPTP  1-methyl-4-phenyl-1,2,3,6-tetra hydropyridine
MPTPp MPTP plus probenecid
MS multiple scerosis
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells 
NMS Non-motor symptoms
NOS nitric oxide synthase
NSAID Nonsteroidal anti-inflammatory drugs 
PD Parkinson's Disease
PPAR Peroxisome Proliferator-activated receptors 
PPREs peroxisome proliferator response elements 
RBD REM behavior disorders 
RLS Restless Legs Syndrome
RNS Reactive Nitrogen Species
ROS Reactive Oxygen Species
RXR retinoic acid receptor 
SN Substantia Nigra
SNc Substantia Nigra pars compacta
SNr Substantia Nigra pars reticulata
STAT3 Signal transducer and activator of transcription 3 
STN Subthalamic nucleus 
TGF transforming growth factor
2
TH tyrosine hydroxylase 
TLR-4 toll- like receptor 4 
TNF tumor necrosis factor 
TZD thiazolidinediones 
UCH-L1  Ubiquitin carboxy-terminal hydrolase L1
VMAT2 vesicular monoamine transporter 2 
YM1 Chil-3 chitinase-like 3
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INTRODUCTION
1. Parkinson's Disease
1.1 History and epidemiology
Parkinson's Disease (PD) was first described in 1817 by an English physician, Dr. James Parkinson,
in his monograph “An essay on the Shaking Palsy”. First defined as “Paralysis agitans”, PD is the
most  common  movement  disorder  (Lee  et  al.,  2009)  and  the  second  most  common
neurodegenerative pathology after Alzheimer's Disease. 
Since incidence of PD is age-related, its social and economic impact is continually increasing with
population ageing (Willis, 2013); PD distribution ranges approximately between 0.5 and 1% of the
population over 60 years (Nussbaum and Ellis, 2003), 1.5- 2% over 65 years (de Rijk et al., 2000),
rising to over 4% in the oldest population (Tanner and Goldman, 1996; de Lau and Breteler, 2006).
Related with estimated increase in number of western population aged over 60 within the next 50
years, an increase in PD spread is expected.  Some studies reported a different prevalence between
males  and females,  with  a  higher  incidence  in  men than in  woman,  probably due  to  potential
neuroprotective effect of oestrogens  (Saunders-Pullman, 2003).
1.2 PD symptomatology: motor and non-motor deficits
PD is clinically characterized by a spectrum of motor  and non-motor  symptoms,  distinctive of
different development  phases of pathology. 
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 1.2.1 Motor symptoms
The cardinal motor symptoms of PD include:
 tremor - the most noticeable early symptom. Tremor, or shaking, often begins in a localized
region – a finger, a hand, an arm- and it usually occurs when the individual is sitting or
standing still;
 akinesia - absence of ability to start voluntary movements. Often begins from legs and arms
(typical is the loss of oscillatory movements of arms in walking). When it affects facial
muscles is cause of hypomimia (“mask face” or “stone face”), a reduced degree in facial
expression; 
 bradykinesia - slowness in execution of movements. They become slower and over time
muscles may randomly "freeze”; 
 rigidity - involuntary amount in muscle tone, which inhibits ability in free movements;
 gait and postural abnormalities, as balance dysfunctions.
 1.2.2 Non-motor symptoms
Non-motor  symptoms (NMS) can  be  present  at  any stage  of  pathological  development  of  PD;
usually, they rise during the early stages of disease and precede the onset of motor signs, reason
why they are also defined as “pre-motor symptoms” (Chaudhuri et al. 2006; Chaudhuri and Naidu,
2008).   NMS  comprise  a  large  variety  of  symptoms,  consisting  of  cognitive,  autonomic  and
neuropsychiatric  disorders   (Chaudhuri  and  Schapira,  2009;  Boeve  BF,  2013;  Kaufmann  and
Goldstein, 2013).
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The most frequent non-motor symptoms include:
 hyposmia – olfactory dysfunction characterized by a reduction of smell.  It's a very early
symptom of PD;
 sleep behavior disorders (RBD) – difficulties with falling asleep (sleep- onset insomnia) and
staying in sleep (sleep- maintenance insomnia), probably associated with other symptoms
such as nocturnal akinesia, nocturia or RLS (Maass and Reichmann, 2013);
 bladder  and urinary dysfunctions  – primarily irritative symptoms,  as increase in  urinary
frequency  and  urgency,  incontinence,  but  also  difficulty  in  initiating  urination  and
incomplete emptying of the bladder (Singer, 1998; Chadauri and Schapira, 2009). Most of
patient also complain nocturia;
 gastrointestinal symptoms – constipation, due to decrease on bowel movements frequency
and impairment in rectal sphincter muscles function;
 sexual dysfunction – erectile dysfunctions, loss of libido or hypersexuality;
 blood  pressure  –  orthostatic  and  postprandial  hypotension,  nocturnal  hypertension
(Ziemssen and Reichmann, 2010);
 restless legs syndrome (RLS) – RLS is defined as the urge to move legs, accompanied or
caused by unpleasant and uncomfortable sensations. It's more frequent during the night, or
in general after periods of  inactivity (Allen et al., 2013);
 dysphagia and dysarthria– difficulty on swallowing and on spoken communication, due to
deficit in muscular function (Tjaden, 2008); 
 depression –  can affect up to 45% of PD patients (Chaudhuri et al., 2006). Depression in PD
patient is typically characterized by a higher frequency of dysphoria, sadness, and suicidal
ideation, and reduced frequency of guilt, self-blame and suicide (Brown et al., 1988);
 anxiety  –  common  in  PD  patients,  especially  in  people  with  depressive  disorders:
comorbidity has been reported between anxiety and depression in PD patients (Henderson et
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al., 1992);
 cognitive impairment – a cognitive decline is observed in PD patients. Deficits on memory
and learning functions, executive functions and slowness of thinking are frequent (Aarsland
et al., 2004).
Non-motor symptoms are often under- recognized and, consequently, under- treated as compared
with motor symptoms, causing a considerably worsening in quality of life of PD patients.
1.3 Histological and biochemical hallmarks of PD
Main pathological feature of PD is the progressive loss of dopaminergic neurons in the Substantia
Nigra pars compacta (SNc, part of Basal Ganglia), accompanied by the presence of typical neuronal
intracellular proteinaceous inclusions containing α-synuclein,  well-known as Lewy's bodies. 
The neuronal death results in a progressive reduction in dopamine (DA) levels, with a  consequent
deficiency of dopaminergic transmission in nigrostriatal pathway.
The Basal Ganglia are a group of interconnected subcortical nuclei, comprising four structures:
 Nucleus Striatum, composed by caudate nucleus, putamen and ventral striatum; 
 Globus pallidus, with an external and an internal section (GPe and GPi);
 Subthalamic nucleus (STN);
 Substantia Nigra, divided in pars reticulata (SNr) and pars compacta (SNc).
In physiological conditions, dopaminergic neurons of SNc project primarily to the Nucleus Striatum
and, to a lesser extent, to GPe and GPi, STN and SNr (Forno, 1996)
Because of  its  strong interconnection with other  brain  structures  as  cortex  and thalamus,  basal
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ganglia circuit is involved in modulating several functions, such us procedural learning, motivation,
cognitive and emotional functions, eye movement and voluntary motor control. This last point is the
main involved in progression of PD. 
Two distinct pathways process the signal through the basal ganglia circuit: 
 direct  pathway,   characterized  by  a  prevalence  of  excitatory  signals  mediated  by
dopaminergic D1 receptor;
 indirect  pathway,  characterized  by  a  prevalence  of  inhibitory  signals  mediated  by
dopaminergic D2 receptor.
Both pathways project to thalamic neurons which make excitatory connections onto cortical cells.
In physiological conditions, the two pathways coexist  in balance, with an excitation in cerebral
cortex  as  final  result.  In  PD,  the  dopaminergic  neurons  death  in  SNc results  in  an  imbalance
between the two pathways in favour of the inhibitory signal, with consequent deficit on cortical
transmission and, finally, in movements control. 
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Fig.1 Basal ganglia circuit.  The picture represents the motor connections in physiological and
pathological conditions, the latter characterized by the unbalance of excitatory (red) and inhibitory
(blue) signalling.
9
Nucleus Striatum
CORTEX
SNc
GPe
STN
Thalamus
GPi
SNr
MOTOR CIRCUIT- NORMAL
excitatory
inhibitory
D1D2
Nucleus Striatum
SNc
GPe
STN
Thalamus
GPi
SNr
excitatory
inhibitory
CORTEX
MOTOR CIRCUIT- PD
D1D2
1.4 Etiology
The etiology of PD is not fully understood, but the main hypothesis considers both environmental
and genetic factors as contributory causes on the disease development.
 1.4.1 Environmental factors
As regard to environmental factors, exposure to a large variety of compounds has been investigated
as a contributing factor in the etiology of PD (Cannon and Greenamyer, 2013). The main event
which  led  to  the  hypothesis  about  a  potential  involvement  of  environmental  toxins  in  PD
development,  was  the discover of 1-methyl-4-phenyl-1,2,3,6-tetra hydropyridine (MPTP) effect  in
rising of parkinsonian symptomatology. In 1983, several people showed the typical PD symptoms
after  intravenous injection  of   synthetic  meperidine  contaminated  by the  neurotoxic  compound
MPTP. This event suggested, for the first time, a correlation between environmental factors and PD
pathology (Burns et al., 1984). 
Moreover, a role of pesticides such as rotenone and paraquat was considered for their involvement
in inhibition of mitochondrial  complex I  and in oxidative stress, showing a positive correlation
between their exposure and PD (Tanner et al.,2011; McCormack et al.,  2005). Because of their
capacity to mimic the pathological hallmarks of PD, such as neuronal death in SNc and formation
of alpha-synuclein inclusions, these compounds are used as experimental models of PD (Langston
et al, 1984; Betarbet et al., 2000; McCormack et al., 2002).
Heavy  metals  such  as  iron,  manganese,  copper,  lead,  aluminium,  or  zinc  have  also  been
hypothesized to increase the risk of PD by accumulation in the Substantia Nigra and by increasing
oxidative stress (Lai et al, 2002), even if epidemiological evidence of an association between metal
exposure and risk of PD has not been totally demonstrated.
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 1.4.2 Genetic factors
Regarding genetic factors, although most cases (about 90%) of PD are sporadic, several single gene
mutations have been identified in familiar PD. A correlation between genetic factors and the disease
seems  to  be  especially  important  in  cases  of  young-onset  PD  (Tanner  et  al.,  1999).  Most  of
identified mutations are presents in genes encoding for proteins involved in oxidative stress and
mitochondrial function. 
In genetic PD nomenclature, 18 chromosomal loci linked to the disease named as PARK have been
identified and numbered in chronological order of their identification; nevertheless,  up to date not
all of them have been  well-characterized  .
The gene PARK1-PARK4/SNCA is involved in alpha-synuclein  mutations (Polymeropoulos et al.
1997 ; Krüger et al., 1998). Mutations in this gene were detected in a large Italian-American family
(Polymeropoulos  et  al.,  1996),  and  subsequently  in  unrelated  Greek  and  German  families
(Polymeropoulos et al., 1997; Krüger et al., 1998).  Patients had a relatively early onset; they also
showed typical clinical and pathological features of PD, including Lewy's bodies. These mutations
result  in  an  autosomal  dominant  pattern,  characterized  by  increased  levels  of  protofibrils,
considered as the most toxic form of the protein which is involved in the formation of Lewy's
bodies.  
Gene PARK2 encodes for Parkin, a component of E3 ubiquitine ligase complex involved in proteins
degradation  by proteasome (Shimura  et  al.,  2000).  Mutations  in  this  gene  are  associated  with
autosomal recessive juvenile PD (Kitada et al., 1998; Matsumine et al., 1998). 
Gene PARK 5 encodes  for Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), a protein with
enzymatic  activity  involved  in  the  development  of  ubiquitin  monomers  and  in
ubiquitin/proteosomal function. A missense mutation in UCH-L1 was detected in two members of a
German family showing autosomal dominant inheritance (Leroy et al., 1998), suggesting a potential
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role  of  ubiquitine/proteosomal system in disease pathogenesis.  However,  no other  cases  of  PD
induced by this kind of mutation have been described, so the real implication of UCH-L1 gene is far
to be demonstrated.
Gene  PARK  6  is  implicated  in  dysfunction  of  PTEN-induced  putative  kinase  1  (PINK1),  a
serine/threonine-protein kinase localized in mitochondria. The main hypothesis is that PINK1 is
involved  in  cell  protection  from  mitochondrial  dysfunction,  triggering  autophagy  of  damaged
mitochondria (Narendra et al., 2010). Mutations in this gene give rise to an autosomal recessive
early-onset PD (Valente et al., 2004).
Protein deglycase DJ-1 plays a protective role within neurons from oxidative stress, showing an
antioxidant effect against ROS (Canet-Aviles et al., 2004). Mutations in the encoding gene for this
protein (PARK 7) are associated with autosomal recessive early-onset PD (Bonifati et al., 2003).
Leucine-rich repeat kinase-2 (LRRK2) is an enzymatic protein with several functions. It is involved
in  several  activities  requiring  protein-protein  interactions,  such  as  assemblage  of  cytoskeletal
structures,  vesicle trafficking, stimulation of stress-activated kinase (Ridley, 2001). Mutations in
the LRRK2 (PARK 8) gene seem to be the most common among identified mutations, in inherited
or sporadic PD: G2019S mutation alone has been reported in 2% to 6% of autosomal dominant PD
families (Di Fonzo et al., 2005; Nichols et al., 2005) and in 2% to 8% of sporadic cases (Gilks et al.,
2005; Deng et al., 2005).
 
1.5 Pathogenesis
Most of environmental  toxins  and genetic  mutations seem to lead to  neuronal  degeneration by
inducing oxidative stress (reactive oxygen or nitrogen species- ROS and RNS- production) as final
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result of different mechanisms, such as mitochondrial dysfunctions, abnormal protein aggregation,
modification on DA metabolism and neuroinflammation (Blesa et al., 2015; Bhat et al., 2015).
 1.5.1 Dopamine metabolism
DA is  synthesized  from  aminoacid  tyrosine  in  two  steps:  (i)  hydroxylation  of  tyrosine  to  l-
dihydroxyphenylanaline (L-DOPA), by tyrosine hydroxylase (TH) and (ii)  decarboxylation of l-
dopa to dopamine, a reaction catalyzed by aromatic amino acid decarboxylase (AADC); then it is
stored  in  synaptic  vesicles  through  the  vesicular  monoamine  transporter  2  (VMAT2).  In
physiological conditions, DA is easily metabolized via monoamine oxidase (MAO) and catechol
ortho-methyltransferase (COMT) to form the  main metabolites  3,  4-dihydroxyphenylacetic  acid
(DOPAC) and homovanillic acid (HVA) as main molecules. Nevertheless, since DA is a relatively
unstable  molecule,  it  may  also  be  susceptible  to  auto-oxidative  mechanisms,  with  consequent
production  of  DA  quinones  (o-quinone),  which  may  alter  in  irreversible  manner  protein
functionality via 5-cysteinyl-cathecols production (Miyazaki et Asanuma, 2008), and free radicals
(O2, H2O2). 
 1.5.2 Mitochondrial dysfunction
The main evidence about a role of mitochondrial dysfunction in PD pathogenesis was based on the
observation that several complex I inhibitors, in particular MPTP, paraquat and rotenone, are able to
reproduce the dopaminergic cell loss in the SNc, in vitro as well as in vivo, in mice and primates
(Manning-Bog et al.,2002; Forno et al., 1986). Moreover, a reduction in complex I activity in the
SNc of PD patients has been well described (Schapira et al., 1990; Hattingen et al., 2009). 
The  inhibition  of  mitochondrial  respiratory  chain  leads  to  ATP  depletion,  with  consequent
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impairment of all ATP-dependent cellular processes, and to the production of free radicals,  with
final  promotion  of  oxidative  stress.  Inhibition  of  complex  I  increases  the  production  of  ROS
superoxide,  which may form hydroxyl  radicals  or react with RNS, to form peroxynitrite:  these
molecules,  beyond worsening mitochondrial  dysfunction by the action on the electron transport
chain itself (Cohen, 2000), may induce cellular damage by acting on lipids, proteins and nucleic
acids (Dauer and Przedborski, 2003).
 1.5.3 Abnormal protein aggregation: role of α-synuclein
The  abnormal  deposit  of  protein  aggregate  is  a  typical  feature  of  several  neurodegenerative
diseases, including PD. In particular, evidences of an association between genetic mutations and
presence of abnormal proteins (e.g. misfolding and aggregation of α-synuclein), or mutant forms of
enzymes ubiquitin-related (parkin, UCH-L1), reveal how modifications in the activity of ubiquitin-
proteasome system (UPS) may play a main role in pathogenesis of PD (McNaught et al., 2001).
Alpha-synuclein is a 140-amino acid protein first described in  Torpedo californica  which has a
possible role in the regulation on dopamine transmission clustering synaptic vesicle by promoting
presynaptic SNARE-complex assembly  (Diao et al., 2013). It is abundantly expressed in nervous
system, with a presynaptic localization in neuronal cells in brain (Tofaris and Spillantini, 2005).
Structurally, α-synuclein does not assume a consistent conformation in aqueous solution, reason
why it is defined as “natively unfolded protein”, but it can acquire an alpha-helic structure after
interaction with lipid membranes (Davidson et al., 1998).  In certain pathological conditions, such
as   PD,  α-synuclein  is  characterized  by conformational  modifications,  assuming  an  oligomeric
configuration termed as  protofibrillar.  Those protein aggregates  is  resistant  to  ubiquination and
contribute to Lewy 's body production in PD (Spillantini et al., 1997), promoting oxidative stress.
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As a final result, these mechanisms cause a general increase of free radicals level, such as ROS and
RNS,  which  promote  oxidative  stress,  and  of  pro-apoptotic  factors  release,  provoking  an
irreversible damage to cellular microenvironment and apoptotic cell death.
In the  last  years,  a  large  number  of  studies  focused their  attention  on neuroinflammation  as  a
potential  underlying  mechanism promoting  neurodegeneration.  Inflammatory  processes  are  not
specific for PD, but contribute to development of several neurodegenerative disorders. Even though
it is not clear whether neuroinflammation represents a first causative event or a consequence of
cellular damage, a body of evidence suggest how neuroinflammation plays a pivotal role  in the
progression  of  neuronal  degeneration  by  producing  deleterious  proinflammatory  and  toxic
molecules. Since modulation of the neuroinflammatory response is the neuroprotective mechanism
postulated for the class of drugs investigated in the present study, the following chapter will focus
on general aspects of immune cells in the brain and on the role of these cells in PD.
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2. Neuroinflammation 
The term “neuroinflammation” includes all the inflammatory processes in central and peripheral
nervous system. The inflammatory process may be caused by a large variety of stimuli, such as
trauma, microbial infections, autoimmunity, toxic metabolites, or it may be part of a degenerative
process (Gendelman, 2002).
Neuroinflammation has become a hot topic in modern neuroscience, with a particular focus on its
potential involvement in development and progression of neurodegenerative disorders such as PD,
Alzheimer's disease (AD), Huntington’s disease and amyotrophic lateral sclerosis (ALS) (McGeer
and McGeer, 2004). Although the role of neuroinflammation in degenerative mechanisms is not
totally understood, evidence of its involvement has opened to the possibility of  new therapeutic
strategies for neurodegenerative disorders (Joers et  al,  2016, in press;  Hirsch and Hunot,  2009;
Akiyama et al., 2000).
The  first  evidence  about  an  involvement  of  neuroinflammatory  mechanisms  in  PD  has  been
provided by post- mortem studies showing the presence of activated microglia in the SN of patients
with PD and parkinsonism with dementia, (McGeer et al., 1988). 
2.1 Microglia and neuroinflammation 
 2.1.1 Microglial cells: role in the healthy brain
Microglia are the resident cells of the central nervous system (CNS) with an immune-competent
role, characterized by an immediate activation in response to even minor pathological changes in
the nervous tissue (Kreutzberg, 1996). This cell population was first defined as “the third element”
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by Ramon y Cajal, to differentiate them from the “first element” (neuron) and “second element”
(astrocyte) (Cajal, 1913 ). In 1921, Pio del Rio- Hortega, a Cajal's disciple, carried a study about the
“third element”, describing microglia and oligodendrocytes as two separate cell populations (del
Rio-Hortega, 1921). 
Microglia represent approximately 10-12% of the whole brain cells and have a mesodermic origin
(del Rio-Hortega, 1932). They derive from hematopoietic precursors, which enter in CNS through
the blood, ventricles and meninges (Cuadro et Navascues, 1998). In the brain, these cells migrate
and proliferate in the form of ameboid microglia, which differentiate into ramified microglia when
they reach their final location, after a period of migration (Dalmau et al., 2003).  
Microglial cells play two main functions in the CNS: tissue maintenance, by keeping  homeostatic
balance, and immune surveillance and defense, by responding to environmental and immunological
stimuli through several effector mechanisms (Ransohoff and Perry, 2009; Nakamura, 2002). 
In the healthy brain, microglia are in a “resting” state showing the typical physiological morphology
with a small rod-shaped soma, ramified and fine cellular processes, even if different variations of
morphology  have  been  observed  also  in  the  quiescent  state  (Kreutzberg,  1996).  Actually,  the
definition of “surveillance” cells seems to fit better than  “resting”: hence microglia are not in a
static  condition,  being characterized by a constant supervising activity of surrounding area for
changes in microenvironment. In a study of 2005, Nimmerjahn showed by using in vivo two-photon
imaging how microglial cells look highly active in their surveillance state: in particular, although
their  soma  generally  remained  fixed  with  few  signs  of  migration,  processes  are  impressively
movable, with rapid extensions and retractions in response to environmental stimuli (Nimmerjahn et
al., 2005).  Functionally, one way that microglia remain in a quiescent state is via the interaction
between the glycoprotein CD200 located on surrounding neurons and the receptor CD200R located
on microglia. 
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Biolegend®
Fig.2. Schematic representation of  neuroinflammation pathways. After compromise of the BBB, T cells
can infiltrate the CNS, releasing cytokines that contribute to neuronal inflammation by activating microglia,
astrocytes,  T cells  and other immune cells.  Chronic neuronal inflammation can lead to release of  toxic
factors  and neuronal death. 
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 2.1.2 Activated microglia display morphological and phenotypical changes 
A large  variety  of  stimuli  such  as  infections,  trauma,  toxins,  changes  in  neuronal  activity  or
dysfunction in physiological brain homeostasis that suggest a potential danger for cerebral tissue,
may  bring  strong  modifications  in  microglia  morphology  and  function,  a  process  known  as
“microglial activation”.  One of the most common methods to study this process in vivo and in vitro
is the employment of the endotoxine lipopolysaccharide (LPS), which binds the toll- like receptor 4
(TLR 4) expressed on the microglial surface, a member of the TLR family involved in the detection
of microbial  intruders (Jack et al., 2005).
The earliest and most evident feature of activated microglia are the morphological changes, which
may assume different features as activation progresses. The classical classification defines as stage
1, early activated microglia, characterized by an enlarged soma and partially retracted and ticker
processes; stage 2, “bushy” or amoeboid microglia, presents short ticker processes and a round-
shaped  soma;  in  stage  3,  phagocytic  microglia,  cells  look  like  large  and  round-  shaped,
indistinguishable from blood macrophages (Kreutzberg, 1996; Ladeby et al., 2005a). However, a
more recent  view argues whether different  morphologies should be considered as stages of the
activation process or rather differential phenotypes depending on the injury or disease type  (Perry
et al., 2010). 
Over  the last  decade  the important  concept  has  emerged that  microglia,  similar  to  other  tissue
macrophages, assume different phenotypes and perform specific effector functions depending on
the precise nature of the stimulus, its intensity and duration (Perry et al., 2010).
Based on the similarities between microglia and macrophages, microglia activation responses were
initially classified using M1/M2 polarization terminology.  Based on this classification, microglia
may assume two main activated phenotypes. Classical activation  M1, promotes neurotoxicity and
pro-inflammatory responses through the release of neurotoxic molecules such as pro-inflammatory
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cytokines, nitric oxide synthase (NOS), reactive oxygene species (ROS), and the  upregulation of
cell  surface markers such as major histocompatibility complex-II  (MHC-II)  and the marker for
phagocytosis  CD86.  Alternative  activation M2,  associated  with  repair  and  healing  or  an  anti-
inflammatory  phenotype,  via  the  production  of  anti-  inflammatory  cytokines  and  neurotrophic
factors (Varnum and Ikezu, 2012). More recently it has become clear that describing the states of
microglia  activation,  as well  as  peripheral  macrophages,  by the M1 and M2 phenotypes  is  not
accurate, as evidence suggests there are many degrees of activation, regarded more as a continuum,
especially  when  considering  the  complexity  of  an  in  vivo environment. For  instance,  M1
macrophages have been defined as M (LPS) or M (INFγ), based on the associated activating factor.
While  both  display  a  pro-inflammatory  phenotype,  different  pathways  of  activation  lead  to
expression of different markers. Similarly, activated microglia may be characterized by the presence
of various markers depending on the stimulating factor (Murray et al., 2014). 
Biolegend®
Fig.2.  Schematic  representation  of  microglial  activation  processes. The  microglia  is  the  resident
macrophage  of  the  CNS  which  can  have  neuroprotective  or  neurotoxic  properties.  Microglia,  under
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classically activating conditions such as stimulation by TNF-α and IFN-γ, adopt an inflammatory phenotype
while stimulation by IL-4 and IL-13 leads to an alternative activated state that reduces inflammation. 
 2.1.3 Microgliosis and microglia phenotypes in PD
Multiple studies have described reactive microglial in post-mortem brain samples of PD patients.
Specifically, major histocompatibility complex class II (MHC-II) immunoreactive microglia were
identified in areas of the SN and striatum in PD patients and in patients with induced parkinsonism
from self-administered MPTP (Langston et al., 1999; McGeer et al., 1988). Located in the vicinity
of the few remaining nigral DA neurons, these microglia displayed morphologies characteristic of
activated and phagocytic cells. More recently, in vivo microglia activation in PD has been described
by increased binding of the marker for activated microglia 11C-PK11195, in the pons, basal ganglia
and frontal and temporal cortex of PD patients compared to age-matched normal controls (Gerhard
et al., 2006). Is is interesting to note that in this study the longitudinal evaluation of 11C-PK11195
binding  suggested  that  there  was  not  a  correlation  with  disease  progression.  While  microglia
proliferation  and  activation  have  been  described  in  PD,  functional  polarization  is  still  little
investigated due to the unavailability of proper in vivo markers for multiple microglia phenotypes,
and to  the fact  that  most  studies  are  performed in the late  disease stage.  Therefore,  it  remains
unclear whether microglia activation may play a protective or cytotoxic role during the earliest
phases of the pathology. These studies have shown that both pro- and anti- inflammatory cytokines
are elevated in the ventricular cerebrospinal fluid  (CSF) of parkinsonian patients, suggesting that
pro-and anti-inflammatory microglia may coexist in parkinsonian brain (Rojo et al.,  2010).  Pro-
inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-2, IL-4, and
IL-6 have been found in serum and CSF  as well as in post-mortem brain of PD patients (Boka et
al., 1994; Mogi et al., 1994a,b; Brodacki et al., 2008). In particular, TNF-α and IL-1β seem to be
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mainly involved in the pathogenesis of neurodegenerative disorders, since it has been shown that
high levels of soluble TNF (solTNF) are a marker of acute and chronic inflammation in PD as well
as in several neurodegenerative conditions such as AD, ALS and multiple sclerosis (MS). Higher
concentrations of IL-1β have been described in dopaminergic striatal regions of PD patients brain as
compared with controls (Mogi et al., 1994a). Not only pro-inflammatory cytokines, but also anti-
inflammatory species including transforming growth factor (TGF)-β and IL-10 occur in CNS or
serum of PD patients, in agreement with the concurrent presence of pro- and anti-inflammatory
microglia (Mogi et al., 1994a; Brodacki et al., 2008). Supporting the hypotheses that an unbalanced
occurrence of pro- and anti-inflammatory microglia may sustain PD neuropathology, higher levels
of pro-inflammatory over anti-inflammatory species has been observed in other neurodegenerative
disorders,  such  as  Alzheimer's  disease   (Hoozemans  et  al.,  2006;  Lund  et  al.,  2006;  Sanchez-
Guajardo et al., 2013). 
More insights on the multiplicity of microglia phenotypes in PD have been provided by studies in
animal models. An increase in surface markers such as major histocompatibility complex class I and
II (MHC-I and MHC-II) and CD68 has been described in different PD models in both rodents and
primates. In addition to cell surface molecules, a number of studies have investigated soluble factors
such  as  cytokines  and  chemokines,  following  administration  of  different  neurodegeneration-
inducing neurotoxins and inflammagens, highlighting their role in DA degeneration and revealing
dynamic  temporal  changes  in  the  production  of  these  molecules  coincident  with  the
neurodegenerative process.  Deficiency of TNF receptors has a neuroprotective role in PD animal
models (McCoy and Tansey, 2008; Sriram et al., 2006). Moreover an overproduction of IL-1β has
been observed in the 6-OHDA model of PD (Pott Godoy et al., 2008). Infusion of TGF-β displays a
dopaminotrophic effect after intrastriatal infusion of 6-OHDA (Gonzalez- Aparicio et al.,  2010),
while in the MPTP model of PD TGF-β mediates GDNF-induced neuroprotection (Schober et al.,
2007). IL-10 is neuroprotective both in the 6-OHDA rat model of PD (Johnston et al., 2008) and
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against the LPS-induced degeneration of the SN (Arimoto et  al.,  2007).  In summary, studies in
animal models of PD suggest that pro-inflammatory microglia may progressively prevail over the
anti-inflammatory  phenotype  along  the  disease  (Pisanu  et  al.,  2014).  Overproduction  of
inflammatory cytokines is an early and persistent event that is associated with microglia activation
from the  early  stages  of  injury,  preceding  and  likely  driving  microglia  polarization  towards  a
phagocytic,  CD68-expressing  phenotype present  in  later  stages  of  neurodegeneration.  Increased
phagocytic  function  clearly  is  not  a  detrimental  feature  per  se,  however  the  upregulation  of
phagocytosis  in  microglial  cells  which  have  mostly  assumed  a  pro-inflammatory phenotype  in
earlier stages of the disease is likely to contribute to progressive neuronal loss (Joers et al, 2016, in
press).
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3. Animal models of Parkinson's Disease
Several types of PD experimental models may be employed in order to reproduce a pathological
condition which models the main features of the disease, with the aim to analyse biochemical and
behavioral changes typical of the disorder.
The main requirement for a model of PD is the presence of a relatively specific and progressive
dopaminergic  neuron  degeneration  in  SNc,  with  an  estimable  motor  impairment  as  behavioral
correlation of nigrostriatal pathway deficit (Dauer et Przedborski, 2003). 
Typically,  they  can  be  divided  into  genetic  models,  which  reproduce  PD-related  mutations,  or
pharmacological models, which use environmental or synthetic neurotoxins. 
Genetic models are based on the involvement of  different mutations (α-synuclein, Parkin, LRRK2,
PINK1, DJ1) in familiar PD cases (Dawson et al., 2010).  Although inheritance in the disease is
quite rare and only 10% of cases may be considered as “genetic” PD, the use of these models allows
to  analyse  the  common mechanisms shared  by genetic  and sporadic  PD,   in  order  to  identify
biochemical and molecular alterations involved in disease pathogenesis.
The  most  largely  used  neurotoxin-  based  models  are  obtained  by  the  administration  of  6-
hydroxydopamine  (6-OHDA)  or  1-  methyl  -1,2,3,6-  tetrahydropyridine  (MPTP)  The  herbicide
paraquat and more recently the natural pesticide rotenone are also used to induce a parkinsonian
syndrome in rodents (Dauer and Przedborski, 2003).
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3.1 MPTP model
 3.1.1 MPTP: finding and history
1  -Methyl-4-phenyl-  1,2,5,6-tetrahydropyridine  (MPTP)  is  a  highly  lipophilic  neurotoxic
compound. It was first synthesized and tested as analgesic in 1947, in order to find a pain-killer less
addictive than morphine, (Lee et al.,  1947), but experimental procedures were interrupted when
Parkinson-like symptoms were observed in primates object of experiments. 30 years later, the 23-
years-old chemistry graduate student Berry Kidston synthesized and self-injected MPPP; within few
days  after  the  first  injection,  he  began  to  show  parkinsonian  symptoms.  After  this  event,  the
National Institute of Mental Health tested the compound on rats, but the study failed because of rat
tolerance to this neurotoxin.
MPTP neurotoxicity became again  object of studies since 1982, when four people in Santa Clara
County,  California,  US,  developed  a  juvenile  severe  parkinsonism after  accidental  intravenous
injections  of  MPTP derived  from the  synthesis  of  1-methyl-4-phenyl-4-propionoxy-  piperidine
(MPPP), a meperidin analogue sold as “synthetic heroin” (Langston et al., 1983). 
Patients showed first symptoms within a week from the first injection, developing a generalized
motor  impairment after 4-14 days; symptoms continued to evolve even after the last injection. 
MPTP administration reproduces the main pathological hallmarks of PD causing a strong loss of
dopaminergic neurons in SNc and compromising the nigrostriatal dopaminergic pathway, with  the
development of typical symptoms including tremor, akinesia and rigidity. The presence of inclusion
bodies has been observed in a progressive model of PD (Meredith et al., 2002), even if there are
conflicting opinions regarding this evidence (Shimoji et al., 2005). In any case, although no Lewy's
bodies have so clearly been detected in these models,  immunoreactivity for α-synuclein  in brain
regions of MPTP-treated primates has been observed (Vital et al., 2010).
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 3.1.2 Mechanism of neurotoxicity
MPTP is a protoxin: after easily crossing the blood- brain barrier because of its high lipophilicity,
the compound is converted to its quaternary derivative 1-methyl-4-phenylpyridium ion (MPP+), the
active metabolite (Langston et al., 1984), by monoamine oxidase type B (MAO B) (Chiba et al.,
1984) in astrocytes and glial cells, with 1-methyl-4-phenyl-3,4,-dihydropyridine (MPDP+) as an
intermediate. Thereafter, MPP+ is released in the extracellular space by a still unknown mechanism;
here, because of its high affinity for membrane dopamine transporter (DAT), MPP+  is uptaken by
dopaminergic neurons, where it exerts the neurotoxic activity. The main cellular target of neurotoxic
damage is the mitochondria:  MPP+ compromises mitochondrial respiration processes by inhibiting
complex I associated to electron transport chain and disrupting the electron flow along the chain
(Nicklas  et  al.,  1985;  Mizuno  et  al.,  1987),   with  a  resulting  impairment  in  oxidative
phosphorylation  and  ATP  synthesis.  Deficit  in  ATP-mediated  processes,  with  an  increased
production of reactive oxygen species (ROS) as a consequence of complex I inhibition (Parihar et
al., 2009) are the two main well-known mechanisms involved in MPTP-related toxicity, even if
recent studies suggest how damages in mitochondrial function can be related to activation of pro-
apoptotic mechanisms. In particular,  it  has been shown that MPP+ may promote the release of
cytocrome C to  the  cytosol,  where  it  can  activate  caspase  activation  and consequent  apoptotic
process (Przedborski and Vila, 2001).
These evidences suggest that the MPTP neurotoxic effect is mediated by several mechanisms; this is
a common point with the pathogenesis of PD which make it an excellent experimental model of PD.
Vulnerability to MPTP toxicity is not the same in all animal species: most of rodents seem almost
immune to MPTP damage, for different metabolic mechanisms (Heikkila et al., 1984; Kopin, 1987);
in particular, rats are strongly resistant to MPTP treatment likely because of their low concentration
of  MAO-B.  The  most  used  species  for  MPTP models  are  mice  and  monkeys,  in  which  PD
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symptoms and mechanisms are better reproduced. The non-human primate model is the one that
better reproduces all the features of human PD, however the development of a comparable model in
small animals such as rodents is fundamental for ethical and economical reasons.
 3.1.3 MPTP acute and subacute protocols 
Acute and subacute MPTP mouse model have been the first protocols of administration tested in
mice. Although different protocols have been used in both models, generally the acute MPTP model
follows  the  protocol  originally  developed  by  Sonsalla  and  Heikkila  (1986),  consisting  in  4
injections of MPTP 20 mg/kg at 1h-2h intervals within a day, characterized by a high mortality; in
the subacute model, mice are typically injected once a day at a dose range from 30 to 20 mg/kg for
4-10 days. Even though acute and subacute treatments may result in a neuronal death in SNc and a
decrease in striatal  dopamine levels,  it  has been shown that these protocols produce a transient
damage, which reverse spontaneously without long term consequences (Petroske et al., 2001).  
 3.1.4 MPTP chronic protocols
The chronic MPTP model is  the most clinically relevant  neurotoxin model,  since it  reproduces
several  typical  features  of  human  PD,  in  particular  the  slow,  progressive  and  non-reversible
neurodegeneration  of  SN  neurons.  In  this  sense,  improved  results  has  been  obtained  by
administration of MPTP simultaneously with probenecid (MPTPp), an adjuvant which inhibits the
rapid renal clearance of the toxin and its metabolites (Betarbet et al., 2002; Petroske et al., 2001;
Meredith et al., 2008; Schintu et al, 2009b). The MPTPp model is carried out for a period of 5
weeks, with twice injections a week, using MPTP at the dose of 25 mg/kg. This model induces a
progressive and irreversible degeneration of SNc dopaminergic cells of 40-50% and a depletion of
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striatal DA of 70-80%, which is reflected by progressive appearance of motor impairment (Meredith
et al., 2008; Schintu et al., 2009b); moreover, a progressive increase of neuroinflammation has been
observed, in terms of microglia activation, unbalance in microglia polarization toward the M1 over
the M2 phenotype, as shown by an increased production of pro-inflammatory cytokines (TNF-α, IL-
1β) and, on the other hand, a decrease of anti-inflammatory cytokines levels (TGF-β, IL-10) (Pisanu
et al., 2014).
Pro-inflammatory cytokines  are  soluble  factors  which  promote  neurodegeneration  mostly via  a
direct  receptor-dependent  mechanism,  which  trigger  initiation  of  pro-apoptotic  pathways  and
further activation of NF-kB. In addition, in 1999 Liberatore et al showed how in MPTP-treated
cytokines stimulate the expression of inducible nitric oxide synthase (iNOS), and the consequent
increase of nitric oxide (NO). NO may then diffuse to neuronal cells where could increase the levels
of nitro-tyrosine, worsen oxidative stress and alter iron metabolism, which is in turn involved in
oxidative stress (Liberatore et al., 1999; Hirsch and Hunot, 2000).
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4. Peroxisome proliferator-activated receptor (PPAR)
Peroxisome proliferator-activated receptors (PPAR) belong to the type II nuclear hormone receptor
superfamily;  they  include  alpha,  gamma  and  delta/beta  subtypes,  encoded  by  different  genes.
PPARs act as ligand-dependent nuclear transcriptional factors, modulating gene transcription by
binding to conserved DNA sequences termed peroxisome proliferator response elements (PPREs),
as an heterodimer with the retinoic acid receptor (RXR) (Kliewer et al., 1992; Berger and Moller,
2002; Michalik et al., 2006). 
4.1 PPARγ 
PPARγ exists in two isoforms, detected in humans and mice: PPARγ 1, ubiquitously expressed in all
tissues, including the brain (localized in several cell types, such as microglia and neurons), and
PPARγ 2, primarily expressed in adipose tissue (Fajas et al., 1997; Cristiano et al., 2001). 
PPARγ were historically studied for their action in regulation of glucidic and lipidic metabolism,
mediated  by  endogenous  ligands  such  as  arachidonic  acid  metabolites  15-deoxy-delta  12,  14
prostaglandin J2 (Forman et al., 1995); experimental data have shown that PPARγ knockout mice
fed with a high-fat  diet  were protected against obesity and insulin resistance as compared with
controls (Jones et al., 2005). 
Besides  endogenous  ligands,  PPARγ is  also  activated  by  the  synthetic  class  of  agonists
thiazolidinediones  (TZDs)  and  few  nonsteroidal  anti-inflammatory  drugs,  such  as  ibuprofen,
fenoprofen and indomethacin (Bernardo and Minghetti, 2008).
In  the  last  decade,  beside  the  main  effects  as  modulators  of  glucidic  and  lipidic  metabolism,
particular  attention  has  been  given  to  PPARγ agonists  for  their  neuroprotective  properties  in
neurodegenerative  disease  models;  evidences  about  this  effect  has  been  shown  in  several
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neurodegenerative conditions, such as PD, AD, ALS and cerebral ischemia (Breidert et al., 2002;
Heneka et al., 2007; Schintu et al., 2009a). 
As regard to PD models, the neuroprotective action has been observed in various kind of MPTP
protocols  based  on acute  and subacute  regimen,  as  well  the  chronic  regimen.   In  acute  MPTP
protocols, the PPARγ agonists pioglitazone prevented dopaminergic loss in SNc and striatal DA
decrease,  and attenuated  the  MPTP-mediated  glial  activation  (Breidert  et  al.,  2002;  Dehmer  et
al.,2004). In the chronic MPTPp protocol, TZD rosiglitazone has shown neuroprotective action by
completely preventing or arresting TH-positive cell death in SNc and partially counteracting loss of
striatal  DA.  Biochemical  results  matched  with  behavioral  data:  chronic  administration  of
rosiglitazone totally prevented olfactory and motor impairment (Schintu et al., 2009b).
As an underlying mechanism of neuroprotection, PPARγ modulation of inflammatory processes has
been proposed.
Modulation of target genes involved in the inflammatory response includes suppression of pro-
inflammatory cytokines and induction of anti-inflammatory molecules, upregulation of antioxidant
enzymes, upregulation of scavenger receptors such as CD36. A well-established mechanism through
which  PPARγ regulates  inflammatory  responses  consider  the  negative  modulation  of  pro-
inflammatory pathways,  such as NF-kB, STAT-3, AP1, and consequent decrease on the production
of  pro-inflammatory  molecules  (Chinetti  et  al.,  2003b).  First  evidences  reported  an  anti-
inflammatory  activity  of  PPARγ agonists in  vitro, by  showing  that  PPARγ agonists  inhibit
inflammatory processes in various cell  types,  including monocytes/  macrophages (Ricote et  al.,
1998) and microglial cells (Combs et al., 2000); moreover, PPARγ activation in microglia prevented
LPS-induced release of nitric oxide, pro-inflammatory cytokines and MHC-II expression (Bernardo
et al., 2000; Luna-Medina et al., 2005). 
Moreover, studies on peripheral immune cells have demonstrated that PPARγ activation stimulates
the polarization of circulating monocytes to macrophages with an M2 anti-inflammatory phenotype,
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which  in  turn  promote  the  switch  of  polarization  from a  pro-  to  an  anti-inflammatory  profile
(Bouhlel et al., 2007).  Based on these evidence, the intriguing hypothesis has emerged that the
potent neuroprotective activity of PPARγ agonists may rely on the ability of polarize immune cells
toward a anti-inflammatory phenotype, while suppressing pro-inflammatory cells. This properties
highly  differentiate  these  drugs  from anti-inflammatory  drugs,  such as  NSAID,  whose  activity
consists on the mere inhibition of inflammatory responses, and would give a likely explanation for
the failure of NSAID to prevent or counteract neurodegeneration.  A large number of in vivo studies
support  the  modulation  of  immune  responses  as  a  mean  of  neuroprotection  in  several
neurodegenerative  pathologies.  In  experimental  models  of   PD, autoimmune encephalomyelitis,
amyotrophic lateral sclerosis and spinal cord injury, the neuroprotective effect of PPARγ agonists
has  been  associated  with  a  decrease  of  pro-inflammatory  and  increase  of  anti-inflammatory
cytokines production (Diab et al., 2004 ; Kiaei et al., 2005; Park et al., 2007; Pisanu et al., 2014). 
In the mice MPTPp model of PD, the chronic administration of rosiglitazone induced an increase of
CD206 levels, a M2 microglia/ macrophage marker, and anti-inflammatory molecules such as TGF-
β  and IL 10, together with a decrease of pro-inflammatory cytokines such as TNF-α and IL-1β
(Pisanu et al., 2014). Therefore, in this study, the PPARγ agonist completely reverted the MPTP-
induced increase of pro-inflammatory microglia in favor of anti-inflammatory phenotype. Boosting
of M2 phenotype, suggesting microglial polarization as a key mechanism for the anti-inflammatory
effect of PPARγ agonists.
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5. MDG548
TZDs such as rosiglitazone, pioglitazone  and troglitazone were originally  introduced in the market
in 1990s as insulin-sensitizing agents for the treatment of type 2 diabetes (Barnett, 2009). After the
discovery of  their  neuroprotective  potential,  this  class  of  compound started  to  be  employed in
preclinical models of a large number of acute and chronic neurodegenerative conditions (Breidert et
al., 2002; Heneka et al., 2010; Park et al., 2007; Schintu et al., 2009b): rosiglitazone effects have
been clinically evaluated in patient with ischemia and AD (Irizarry et al., 2008).
Over time, safety concerns have been raised about TZDs safety in diabetic patients: troglitazone
was removed from the market because of its hepatotoxicity (Smith, 2003), and rosiglitazone and
pioglitazone   were  objects  of  multicentre  studies  with  the  purpose  to  analyse  a  potential
involvement in cardiovascular disorders in patients with diabetes (Home et al., 2009; Dormandy et
al., 2005). Both rosiglitazone and pioglitazone have been related to an increase of LDL cholesterol
levels, fluid retention and increased body weight (Nesto et al., 2003) and, moreover, TZDs  have
been associated with an increase of cardiovascular risk by promoting high levels of blood pressure
and coagulation factors (Komajda et al., 2008).
This limitation has prompted for the search of novel non-TZD compounds void of such side-effects.
MDG548  is a novel thiobarbituric-like compound recently identified by computational integrated
virtual screening, displaying specific PPARγ binding with an affinity approximately double that of
rosiglitazone (Nevin et al., 2012). The neuroprotective potential of MDG548 was evaluated by in
vitro and  in vivo tests. The high potency  of the compound, which permit to employ lower doses
than TZDs, associated with the non-TZD structure, might reduce the risk of unwanted side effects.  
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Part of the data discussed in this thesis has been already published in the paper “Neuroprotective
and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist  in vitro and in
MPTP-treated mice”. That study has been conducted in collaboration with the Biochemistry Group
of the Trinity College of Dublin, where TCD performed all in vitro experiments aimed at assess
effective doses and the neuroprotective potential  of MDG548, while our group investigated the
neuroprotective and anti-inflammatory properties of the compound  in vivo in a subacute MPTP
mouse model of PD. For clearness, results of  in vitro experiments conducted by TCD have been
inserted in the present thesis, representing the basis for a rational  in vivo testing.  The remaining
data presented in the thesis have been submitted for publication in Experimental Neurology Journal.
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AIM OF THE STUDY
Therapeutic  management  of  neurodegenerative  disorders  is  a  crucial  social  aim,  because  of
improvement of life expectation, and consequent increase of age-related pathologies.
Currently, available therapies for PD are strictly symptomatic. Since the first signs of the disease
appear when the dopaminergic degeneration in SNc is already in a late stage (about 70%) (Dauer
and Przdeborski, 2003), current therapeutic approaches focus on the symptomatic control of motor
symptoms. Nowadays, the gold standard therapy for PD patients is the DA precursor L-DOPA.
Nevertheless, a long-term use is usually associated with the onset of motor complications, including
dyskinesia (Olanow et al., 2001).
Therefore, research is highly focused on the understanding of neuropathological mechanisms of PD
which may serve as targets for disease-modifying therapies aimed at arrest disease progression.
PPARγ agonists hold a promising disease-modifying potential,  since they are neuroprotective in
several preclinical models of PD.
Aim of the present study was to characterize the neuroprotective properties of the PPARγ agonist
MDG548, a new no TZD compound displaying high selectivity and binding affinity for PPARγ, in a
preclinical  model  of  PD.  Immunomodulatory  properties  of  MDG548  were  investigated  as  a
supposed underlying mechanism of neuroprotection. Microglia phenotypes were investigated in in
vivo PD models. Moreover, since the quite ubiquitous localization of PPARγ in CNS cells does not
allow to investigate direct effects selectively on microglia,  in vitro studies were carried to deeply
investigate PPARγ effect on these cells.  
The whole study was made in collaboration with local and international research groups. All the
experiments are presented in this thesis for completeness and better understanding of the data. Roles
of our group as well as collaborators are specified below.
The group from the School of Biochemistry & Immunology of TCD performed in vitro experiments
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aimed  at  assessing  effective  doses  and  the  neuroprotective  potential  of  MDG548  in  cultured
neurons.
Our  research  group  performed  all  in  vivo treatments  and  fluorescent  immunohistochemistry
experiments ex vivo as well as in vitro in cultured microglia. 
Dr. Andrea Diana group, from our Department of Biomedical Sciences, prepared MMGT12 cultures
and made in vitro pharmacological treatments.
Dr.  Barbara Batetta group, from our Department of Biomedical Sciences,  performed all  ELISA
assays in microglia collected medium.
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MATERIALS AND METHODS
1. Drugs
For  in  vitro studies,  MDG548  (Specs  ID  number:  AN-698/  15136006;  5-[4-(benzyloxy)-3-
chlorobenzylidene]-2-  thioxodihydropyrimidine-4,6(1H,5H)-dione;  Mol.  Weight:  372.83)  and
rosiglitazone (Santa Cruz) were dissolved in 0.1% dimethyl sulfoxide (DMSO). 
For in vivo studies, MPTP-HCl (Sigma, Italy) was dissolved in saline. MDG548 was suspended in
30% DMSO, 10% polyethylene glycol (PEG) and water.
For chronic treatment,  probenecid (Sigma Aldrich, Italy) was suspended in 5%  NaHCO3;  PPARγ
antagonist GW9662 (Sigma Aldrich, Italy) was suspended in 5% DMSO and water.
2. In vitro tests
2.1 Primary culture of cerebral cortical neurons
Primary cerebral cortical  neurones were obtained from postnatal  1-day-old Wistar rats.  Cortical
tissue was incubated with 2 ml sterile phosphate-buffered saline (PBS) containing trypsin (0.3%;
Sigma–Aldrich,  Dorset,  UK) in  a  humidified  chamber  for  25 min  at  37°  C,  followed by PBS
containing soyabean trypsin inhibitor (0.1%), DNAse (0.2 mg/ml) and MgSO4 (0.1 M) (all from
Sigma–Aldrich, Dorset, UK). The cell suspension was gently filtered and centrifuged at 2000g for 3
min at 20° C. The pellet was resuspended in neurobasal medium (NBM, Invitrogen, Paisley, UK),
supplemented with heat-inactivated horse serum (10%) penicillin (100 U/ml), streptomycin (100
U/ml) and glutamine (2 mM) (all from Gibco BRL, Maryland, USA). Resuspended neurons were
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placed on coverslips at a density of 0.25x106 and incubated with NBM containing 5 ng/ml cytosine-
arabino-furanoside (ARA-C; Sigma–Aldrich, Dorset, UK) for 24 h to prevent proliferation of non-
neuronal  cells.  Cells  were  grown in  NBM (400 μl/well)  media  for  up  to  5  days  post  ARA-C
treatment.
2.2 CalceinAM cell viability assay
Cells were treated with MDG548, rosiglitazone or vehicle (0.1% DMSO) and allowed to incubate
for 24 or 48 h prior  to  the addition of calceinAM (2 μM) at  the experimental  endpoint.  After
incubation (30 min at  37° C),  fluorescence intensity (Ex:  495 nm, Em: 515 nm) derived from
cleaved calcein retained within viable cells was read on a Spectramax Gemini fluorometric plate
reader using SOFTmax Pro (V4.0, Molecular Devices) software package. Data were presented in
relative fluorescence units (RFU).
2.3 PrestoBlue cell viability assay
For the PrestoBlue assay, cortical neurons were analyzed in two experimental conditions: (A) pre-
treatment with MDG548 or rosiglitazone for 24 h prior to exposure to H2O2 (50 μM), and (B) co-
treatment  with  MDG548  or  rosiglitazone  and  H2O2 (50  μM)  at  the  same  time  point.  In  both
instances,  cortical  neurons  were  incubated  for  a  further  24  h  prior  to  measurement  of  cellular
viability. MDG548 or rosiglitazone were added at increasing concentrations (100 nM to 10 μM).
Based  on  results  of  MDG548-mediated  neuroprotection,  in  a  following  experiment  PPARγ
antagonist  GW9662  was  added  1  h  prior  to  MDG548  and  the  experimental  condition  A was
followed.  PrestoBlue reagent  is  reduced to  a  highly fluorescent  compound by the reducing the
environment  of  the  viable  cell.  Fluorescence  intensity  was  assessed  as  a  directly  proportional
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measure of the amount of viable cells.
2.4 Neutral red uptake assay for cell viability/cytotoxicity
PC12 cells,  the  rat  adrenal  pheochromocytoma cell  line,  were  purchased  from American  Type
Culture Collection.  Cells  were grown on poly-L-lysin-coated flasks (100 μg/ ml) in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 1% L-glutamine and
1% penicillin/streptomycin (all from Sigma–Aldrich). All cells were cultured at 37° C with 5%
CO2. In order to ensure the expression of dopaminergic features, 104 cells per well were seeded in
24 well plates and immediately treated with NGF (50 ng/ml) every second day so that neuronal
differentiation was achieved after 10 days. At that time, the complete medium was replaced by the
same medium but with lower (1%) concentration of FBS to avoid the risk of any possible protein
interference on the assay sensitivity. GW9662 (1 μM) or vehicle was added 1 h prior MDG548 (500
nM and 5 μM) plus MPP+ (500 μg/ml). After the scheduled treatment, cells were briefly washed
with PBS and incubated with neutral red solution (40 μg/ml) for 3 h at 37° C in the dark. This assay
is based on the ability of viable compartments (Repetto et al., 2008). After 3 h, neutral red solution
was removed and after gentle immersion in PBS, neutral red destain solution (50% ethanol, 95%,
49% deionized water, 1% glacial acetic acid) was applied for at least 10 min in agitation to allow
the  complete  extraction  of  the  red  chemical  from  cells  and  the  formation  of  a  homogeneous
solution. Neutral red extract was measured at 540 nm in a microtiter plate reader spectrophotometer
using blanks with no cells for measurement normalization. Finally, cell viability was expressed as a
percentage of control cells (100%).
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2.5 HEK-Blue   NF-kB reporter assay
HEK-Blue reporter assay was performed using HEKBlue -hTLR4 cells (Invivogen, Carlsbad, CA,
USA).  Stimulation  of  TLR4  with  LPS  induces  rapid  activation  of  NF-kB  and  a  correlated
expression of Secreted Embryonic Alkaline Phosphatase (SEAP). HEK-Blue cells were seeded at a
density of 0.25x105 cells/well and pre-treated for 24 h with vehicle (0.1% DMSO), or increasing
concentrations of MDG548 or rosiglitazone in association with vehicle or the PPARγ antagonist
GW9662. Post-incubation, cells were treated with LPS (100 ng/ml) and further incubated at 37° C
for 6 h. The proteasome inhibitor MG132 was included as a control.  Quanti-Blue analysis  was
performed by incubating 20 μl of HEK-Blue supernatant with 180 μl of Quanti- Blue media in the
dark at  37° C for 2–4 h. SEAP-induced changes from a pink to blue color were monitored by
reading absorbance (650 nm) on a Versamax absorbance plate reader.
2.6 Culture of murine microglial cell and in vitro immunohistochemistry
The murine microglial cell line MMGT12 (Briers et al., 1994; Michelucci et al., 2009; Heurtaux et
al., 2010), a generous gift from Dr. Michelucci was cultured in DMEM/F12, supplemented with
10% fetal bovine serum (FBS). No antibiotics were used. The cells were grown in a humidified
atmosphere of 5% CO2  at 37°C and passaged twice a week. For experiments (both ELISA and
immunocytochemistry), MMGT12 cells were seeded into 12 multiwell plates previously filled with
coverslips 18 mm diameter size. Cellular density was set to 15x103/well in order to ensure to reach
70% confluence  by adhesion to the coverslips at 3 days in vitro (DIV) when most of cells presented
a common morphological appearance. Cells were subjected to incubation in a medium containing
5%  FBS  according  to  table  1.  After  24  h  treatment,  exposure  media  were  saved  for  ELISA
experiments  and  cells  were  washed  in  PBS.  Then,  all  specimens  were  fixed  with  4%
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paraformaldehyde/PBS for 15 min at room temperature (RT) with gentle agitation. Fixative solution
was  replaced  with  PBS  and  immediately  samples  were  processed  for  immunocytochemical
technique. After three rinses in the same buffering solution, cells were transferred for 5 min in 0.2%
TritonX-100 containing PBS and then preincubated with 10% normal non immune serum (Sigma)
for 1 h. Primary antibodies were rabbit anti-CD68 (Abbiotec) diluted 1.200 in PBS/0.2% TritonX-
100 overnight at 4°C. Subsequently, after 3x5 min. rinsing steps in the same PBS/triton solution,
detection with secondary antibodies (Molecular Probes, USA) was carried out using Alexa Fluor
546  F(ab’)2  fragment  of  goat  anti-rabbit  IgG  (1:200)  for  1  h  incubation  time  at  RT.  Nuclear
counterstaining was performed with DAPI, dihydrochloride solution (300nM in PBS, Molecular
Probes, USA) and finally, samples were washed and mounted in 70% glycerol in PBS containing
1% DABCO (Sigma-Aldrich, U.S.A.) as anti-fading agent.
Observations and images were captured using ZOE fluorescent cell imager (Bio-Rad) as TIFF files
with a resolution of 647 × 486 pixels.
Treatments MDG548
concentration
MDG548 time administration
Controls (+0.1% DMSO as vehicle)
LPS 1 μg/ml (1mg/ml DMSO) 
MDG548
MDG548
LPS 2h +MDG548s
LPS 2h +MDG548s
LPS 2h +MDG548c
LPS 2h +MDG548c
10 μM
50 μM
10 μM
50 μM
10 μM
50 μM
2h after LPS
2h after LPS
contemporaneous with LPS
contemporaneous with LPS
Table 1: MMGT12 cell treatment for immunocytochemistry and ELISA. LPS and MDG548 were solved
in DMSO (0.1% final concentration).
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2.7 Cytokines quantification by ELISA assay 
Cells  were  removed  by 400  g  centrifugation  for  10  min  and  supernatants  frozen  at  80°C  for
subsequent determination of mouse TNF- , Ym1 (EIAab Science, Wuhan, China), CD206 (Cloud-
Clone Corp., TX, USA). Cytokines were assessed with a sandwich ELISA test  as described by
manufactures guidelines. Absorbance at 450 nm for all cytokines was measured with a microplate
reader, model 680 (Bio-Rad, Hercules, CA). A standard curve was prepared by plotting absorbance
value of the standard cytokine versus the corresponding concentration (pg/ml or ng/ml). The range
of assay for cytokines:  15.6–1,000 pg/ml  for TNF-α, 78.0-2500 pg/ml for  Ym1 and 15.6-1000
pg/ml for CD206.
3. In vivo methods
3.1 Subacute treatment
Three-month-old male C57BL/6J mice (Charles River, Italy) were divided into six groups (n=4/5
for each group) and housed with a 12:12-h light/dark cycle with food and water ad libitum. Mice
received multiple injections treatment with saline as a vehicle, MPTP-HCl (20 mg/kg i.p.) once a
day for 4  days, or MDG548 (2, 5 or 10 mg/kg i.p.) plus MPTP (20 mg/kg i.p.) once a day for 4
days. MDG548 was injected 15 min before MPTP administration. Three days after discontinuation
of  treatment,  mice  were  anaesthetized  with  chloral  hydrate  (400 mg/kg i.p.)  and transcardially
perfused with 4% paraformaldehyde (PFA)/0.1M in phosphate buffer (PBS).
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3.2 Chronic treatment
Three-month-old male C57BL/6J mice (Charles River, Italy) were divided into six groups (n=5-10
for each group) and housed with a 12:12-h light/dark cycle with food and water  ad libitum. The
control group received saline as a vehicle, groups MPTP3, MPTP7 and MPTP10 received 3, 7 and
10 doses of MPTP (25 mg/kg i.p.) respectively, plus probenecid (100 mg/kg i.p.) (MPTPp). MPTPp
was injected twice a week up to 5 weeks. Group MPTP+MDG548 (MM) received 10 doses of
MPTPp over 5 weeks and the PPARγ agonist MDG548 (2 mg/kg i.p., 15 minutes before MPTPp
injection)  starting  on  the  2nd day  after  the  seventh  MPTPp  administration.  Group
MPTP+MDG548+GW9662  (MMG)  received  MPTPp+MDG548  at  the  same  conditions  of
MPTP+MDG548  group,  with  administration  of  PPARγ  antagonist  GW9662  (5  mg/kg  i.p.)  15
minutes before MDG548 injection. For both MM and MMG groups, MDG548 was administered
daily, 15 minutes before MPTPp and until sacrifice. Three days after discontinuation of MPTPp
treatment, part of mice were anaesthetized with cloral hydrate (400 mg/kg i.p.) and transcardially
perfused with 4% PFA /0.1 M PBS. Brain were removed, postfixed in PFA for 2 hours and stored in
0.1% sodium azide PBS at 4°C until immunohistochemical processing. All animal experimentation
has been conducted in accordance with the guidelines for care and use of experimental animals of
the European Communities Council Directive of 24 November 1986 86/609/EEC and the National
Institutes of Health.
3.3 Beam traverse test  
The  beam  was  constructed  as  described  (Fleming  et  al.,  2004).  Mice  were  trained  for  two
consecutive days to traverse the beam. On the test day a grid (1 cm2) of corresponding width was
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placed 1 cm above the beam, mice were videotaped while traversing it for a total of ﬁve trials, and
errors  were  calculated  (when  a  limb  slipped  through  the  grid).  By  scoring  each  limb  slip
individually, the severity of the error could be measured (Fleming et al., 2004).
3.4 Immunohistochemistry/Immunofluorescence
Coronal sections from the SNc (40 μm thick) were cut on a vibratome and immunoreacted against
tyrosine hydroxylase (TH), CD11b, iNOS, TNF-α and CD206.
TH-positive cells were visualized using a TH antibody (anti- TH monoclonal antibody produced in
rabbit 1:1000, Sigma-Aldrich, Italy). After washing in PBS, sections were incubated for 1 hour with
the secondary antibody (IgG (H+L) Biotin-Goat anti-rabbit 1:500, Invitrogen, Italy) and the classic
avidin-peroxidase complex (ABC, Vector, UK) protocol was applied, using 3,30- diaminobenzidine
(Sigma) as a chromogen.
For  CD11b  and  iNOS  immunofluorescence,  sections  were  incubated  overnight  with  a  CD11b
antibody (anti-  CD11b monoclonal  antibody produced in rat  1:1000, Serotec,  Oxford) or iNOS
(anti-iNOS monoclonal antibody produced in rabbit 1:400, Santa Cruz, Germany) plus TH antibody
(anti-TH  monoclonal  antibody  produced  in  mouse  1:1000,  Sigma  Aldrich,  Italy).  After  PBS
washing,  sections  were  incubated  with  a  goat  anti-rat  secondary  antibody  AlexaFluor  594-
conjugated immunoglobulin G (IgG, 1:200, JacksonImmunoResearch Europe, UK) for 4 hours for
CD11b. 
For iNOS/TH double labeling, AlexaFluor 594-conjugated immunoglobulin G (IgG (H+L) donkey
anti-mouse 1:500, Invitrogen, Italy) was used to detect TH, while a three-step detection was used to
increase the signal of iNOS by biotin-conjugated IgG (biotin-conjugated donkey anti-rabbit 1:200,
Jackson ImmunoResearch Europe, UK) and  treptavidin–fluorescein (1:200, Vector, UK). 
For CD11b/TNF-α double labelling, sections were incubated 48 hour with CD11b antibody and a
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TNF-α antibody (TNF-α polyclonal rabbit anti-TNF-α 1:800, Abbiotec, USA); after PBS washing,
sections were incubated with secondary antibody for CD11b while three-step detection was used to
increase the signal of  TNF-α by biotin-conjugated IgG (IgG (H+L) Biotin-Goat anti rabbit 1:500,
Invitrogen, Italy) and streptavidin–fluorescein (1:200, Vector, UK).  
For CD11b/CD206 double labelling, sections were incubated 48 hour with CD11b antibody and
CD206 antibody (CD206 polyclonal goat anti CD206 1:500, Santa Cruz Biotecnology, CA); after
washing in PBS / 0.2% Triton X-100 sections were incubated with secondary antibody for CD11b,
while  three-step  detection  was  used  to  increase  the  signal  of  CD206  by  combining  biotin-
conjugated  IgG  (IgG  (H+L)  Biotin-rabbit  anti  goat  1:500,  Invitrogen,  Italy)  and  streptavidin–
fluorescein (1:500, Vector, UK).
To allow visualization of cell nuclei (not shown in figures), sections were incubated for 5 minutes in
5 μM Hoechst 33258 (H 33258) solution (Sigma, Italy). 
3.5 Stereological counting of TH-immunoreactive and Nissl-stained neurons
TH-immunoreactive  and  Nissl-stained  cells  were  counted  on  both  hemispheres.  Each  mounted
section  was  numbered  following  rostro-caudal  levels  corresponding  to  the  mouse  brain  atlas
(Paxinos and Franklin, 2001) and every sixth section was used for cell number estimation. We used
a  dedicated  software  (Stereologer,  System Planning  and  Analysis,  Inc.,  Alexandria,  VA,  USA)
linked to a motorized stage on the BX-60 Olympus light microscope. The total number of TH-
immunostained cells was estimated by means of the Optical Fractionator method, which combines
the optical dissector with the fractionator sampling scheme, giving a direct estimation of the number
of 3-D objects unbiased by their shape, size and orientation (Mouton, 2002). After delimitation of
the area of interest based on clearly visible cues using a 2 objective, a systematic random sampling
of cells was achieved by positioning a sampling grid over the area on each section, automatically
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operated by ‘‘Stereologer’’ program. The grid was divided into equidistant counting frames (frame
area=50 μm2). The sampling fraction was delimited at low power and cells were sampled with a 40
oil immersion objective through a defined depth with a guard zone of 2 μm. The coefficient of error
(CE) for each estimation and animal ranged from 0.05 to 0.1.
3.6 CD11b analysis
CD11b-positive microglia were identified at ×100/1.25 oil magnification. For each animal six fields
of SNc were captured from both the left and right SNc and analyzed; for each microglial cell, the
body and primary processes were outlined, and the area occupied by CD11b immunoreactivity (IR)
was measured using NIH software ImageJ 1.47v.
3.7 iNOS analysis
Images of iNOS-positive cells were captured at ×40 magnification. The SNc was surrounded and
the same boundary applied to each section; for each animal, three fields were sampled in both left
and right SNc. Cells were automatically counted using Media Cybernetics software Optimas 6.51.
3.8 CD11b/TNF-α and CD11b/CD206 colocalization analysis  
Qualitative and quantitative analyses for CD11b and CD206 were performed using a Leica 4D
confocal laser scanning microscope, equipped with an argon–krypton laser. Images were digitized
24  h  after  the  immunofluorescence  procedure.  Surface  rendering,  maximum  intensity,
colocalization, and simulated fluorescence process algorithms were used (ImageJ 1.48q and Imaris
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7.0). Volume of colocalized elements was determined as follows: for each dataset (40–60 images), a
colocalization  channel  was automatically composed by Imaris  7.3.  In  the resulting  stacks,  four
regions of interest (x= 40  μm; y= 40  μm; z= 10  μm) were randomly chosen and volume of the
elements of interest was calculated, summed and expressed as volume/μm3 (n= 200).
4. Statistics
For  in vitro assays, MDG548-treated cells were compared to the relative control cells by using a
two-way analysis of variance (ANOVA) with Bonferroni post hoc test. Stereological measures of
TH  and  Nissl-positive  cells  in  the  SNc,  as  well  as  CD11b  and  iNOS  data  were  statistically
compared with a one-way ANOVA followed by Tukey’s post hoc test.
For behavioral test, number of errors was statistically compared with a one-way ANOVA followed
by Tukey's post-hoc test.
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RESULTS
1. Neuroprotective potential and immunomodulatory properties of MDG548 in cultured cells
Determination of MDG548 cytotoxicity against rat cortical neurons
In  order  to  determine  a  concentration  range  void  of  cytotoxicity  in  which  to  assay  the
neuroprotective effects of MDG548, the cell viability of cortical neurons was assessed at 24 and 48
h after  treatment  with  increasing  MDG548 concentrations.  The CalceinAM cell  viability  assay
showed a dose-dependent cytotoxicity for MDG548 (Fig. 3). When compared to the control (0.1%
DMSO) MDG548 induced a significant reduction in viability at 50  μM 24h (p<0.05) and 48 h
(p<0.001) post-treatment, while lower concentrations were void of any cytotoxicity (Fig. 3A, B).
Rosiglitazone, a marketed drug that acts as a high affinity PPARγ agonist displayed an effect on cell
viability similar to MDG548 (Fig. 3A, B).
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Fig. 3. Determination of MDG548 cytotoxicity against rat cortical neurons. Cells were treated with vehicle
(DMSO 0.1%) or increasing doses of MDG548 or rosiglitazone, and allowed to incubate for 24 (A) or 48 h
(B) prior to addition of CalceinAM (2  μM) at the experimental endpoint.  Data are presented in relative
fluorescence units  (RFU).  Test  wells  were compared to  vehicle  treated (0.1% DMSO) using a two-way
ANOVA with Bonferroni post hoc test. *p<0.05, **p<0.01, ***p<0.001. Error bars represent the Standard
Error  of  the  Mean  (SEM).  Experiments  were  carried  out  in  triplicate  in  at  least  three  independent
experiments.
MDG548 exposure protected rat cortical neurons from H2O2-mediated injury
The protective effect of MDG548 was assessed in cultured rat cortical neurons exposed to H2O2.
Two  experimental  conditions  were  studied,  where  neurons  were  exposed  to  MDG548  or
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rosiglitazone either 24 h prior to H2O2 exposure (Fig. 4A) or at the same time point (Fig. 4B), and
incubated for a further 24 h prior to measurement of cellular viability via PrestoBlue assay. The
non-cytotoxic  concentration  window  previously  determined  was  used  for  MDG548  and
rosiglitazone  (100  nM–10  μM).  In  both  experimental  conditions,  neuronal  viability  was
significantly reduced after exposure to H2O2 when compared to the control vehicle (0.1% DMSO)
(p<0.001).  Pre-treatment  (24 h)  of cortical  neurons with increasing concentrations of  MDG548
resulted in a dose-dependent raise in cell viability as compared to H2O2-treated cells, displaying
significant values at 500 nM concentration (p<0.05) and 1.0 to 10 μM concentration (p<0.001) (Fig.
4A).  Pre-treatment  (24  h)  with  rosiglitazone  also  displayed  significant  neuroprotective  effects
against H2O2 at 1.0 μM (p<0.05) and 5.0 to 10 μM (p<0.001) doses (Fig. 4A). MDG548/H2O2 co-
treatment induced a limited  increase in cortical neurons viability at 1 μM (p<0.01) and 5 to 10 μM
concentrations  (p<0.001)  when  compared  to  H2O2 (Fig.  4B).  In  this  experimental  condition
rosiglitazone  increased  cell  viability  at  10  μM  concentration  only  and  to  a  very  small  extent
(p<0.05).  Exposure to the PPARγ antagonist  GW9662 (1  μM) for 1 h prior  to incubation with
MDG548 in experimental condition A abrogated the neuroprotective effect (Fig. 5). The PPARγ
antagonist was not tested in experimental condition B since MDG548 yielded a very small effect in
this test while rosiglitazone mostly displayed no effect. Neuronal viability was not significantly
different following exposure to the antagonist alone (Fig. 5).
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Fig. 4.  MDG548 exposure protects rat cortical neurones from H2O2-mediated injury. Cells were treated
with vehicle (0.1% DMSO), MDG548 or rosiglitazone 24 h prior to addition of H2O2 (50 μM) (A) or at the
same time-point than H2O2 (B). Data are presented in relative fluorescence units (RFU). Test wells were
compared to H2O2 treated (0.1% DMSO) using a two-way ANOVA with Bonferroni post hoc test.  *p<0.05,
**p<0.01, ***p<0.001, ^^^p<0.001 versus vehicle (0.1% DMSO). Error bars represent the Standard Error
of the Mean (SEM). Experiments were carried out in triplicate in at least three independent experiments.
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Fig. 5. PPARγ antagonist GW9662 inhibits the neuroprotective effects of MDG548. Cells were treated with
GW9662 (1 μM) or vehicle (0.1% DMSO) for 1 h prior to treatment with MDG548 or vehicle, and allowed
to incubate for 24 h prior to addition of H2O2 (50  μM). Data are presented in relative fluorescence units
(RFU).  Test  wells  were  compared  to  H2O2-treated  cells  (0.1% DMSO)  using  a  two-way  ANOVA with
Bonferroni  post  hoc test. **p<0.01,  ***p<0.001.  ^^^p<0.001 versus  vehicle (0.1% DMSO).  Error bars
represent the Standard Error of the Mean (SEM). Experiments were carried out in triplicate.
MDG548 protected PC12 dopaminergic-like cells against MPP+-induced toxicity
Neuroprotection by MDG548 was assessed in NGF differentiated PC12 cells exposed to MPP+
(Fig. 6). NGF was added in order to confer dopaminergic-like features to cells. Neuronal viability
was significantly reduced after exposure to MPP+ when compared to the control vehicle (0.1%
DMSO) (p<0.001). Exposure to GW9662 alone also reduced cell  viability,  although to a lesser
extent than MPP+ (p<0.01). Treatment of PC12 cells with increasing doses of MDG548 induced an
increase  of  cell  viability  (p<0.001),  which  was  attenuated  by  exposure  to  GW9662  (1  μM)
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(p<0.001) (Fig. 6).
Fig. 6. MDG548 exposure protected PC12 dopamine-like cells from MPP+ toxicity. Cells were treated with
GW9662 (1 μM) or vehicle (0.1% DMSO) for 1 h prior to treatment with MDG548 or vehicle plus MPP+.
Data are presented in % of viable cells, and a two-way ANOVA with Bonferroni post hoc test was applied for
statistical analysis. ^; ^^p<0.01 or 0.001 versus vehicle (0.1% DMSO), **p<0.01, ***p<0.001. Error bars
represent the Standard Error of the Mean (SEM). Experiments were carried out in triplicate in at least three
independent experiments.
MDG548 inhibited LPS-induced activation of NF-kB
HEK Blue cells were treated with increasing concentrations of MDG548 or rosiglitazone for 24 h
prior to stimulation with LPS (100 ng/ml) for a further 6 h. MG132, a known inhibitor of NF-kB
activation was also included alongside LPS-stimulated/unstimulated controls. Stimulation with LPS
but not LPS and MG132 resulted in activation of NF-kB compared to controls (p>0.01), as reported
by the increase in absorbance. Pre-treatment with MDG548 induced a dose-dependent decrease in
LPS-stimulated  NF-kB  activation  as  compared  to  LPS  alone,  which  was  significant  at
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concentrations 1.0 to 50 μM (p<0.01) (Fig. 7A). MDG548 itself did not induce NF-kB activation in
non-LPS-stimulated treatments, at any tested concentration (p  >0.01). As expected, rosiglitazone
also showed a reduction in NF-kB activation, but only at 25 and 50μM (p<0.01) (Fig. 7B). Inclusion
of the PPARγ  antagonist  GW9662 did not abolish MDG548 and rosiglitazone effect on NF-kB
activation (p<0.01) (Fig. 7A, B).
53
Fig. 7.  MDG548 inhibits NF-kB activation in a dose-dependent manner.  Cells were treated with control
solutions  or  increasing  concentrations  of  MDG548  or  MDG548+GW9662  (1  μM)  (A),  or  increasing
concentrations of rosiglitazone or rosiglitazone+GW9662 (1 μM) (B), and allowed to incubate for 24 h prior
to addition of LPS (100 ng/ml). Data are presented in arbitrary absorbance units. Test wells were compared
to 0.1% DMSO+LPS-treated cells using a two-way ANOVA with Bonferroni post hoc test. ***p<0.01. Error
bars represent the Standard Error of the Mean (SEM). Experiments were carried out in triplicate in at least
three  independent  experiments.  C  depicts  an  XY  plot  of  absorbance  versus  log  concentration  (M)  of
MDG548 and is representative of a decrease in NF-kB activation under MDG548+LPS and MDG548-only
treatments.
MDG548 altered microglia phenotype in LPS-stimulated MMGT12
In murine microglial cells MMGT12, MDG548 showed a dose-dependent effect on the levels of
pro- and anti-inflammatory molecules measured by ELISA. 10  μm but not 50  μm of MDG548
significantly decreased TNF-α levels and increased CD206 levels in untreated cells, as compared
with vehicle (p<  0.05 for TNF-α; p< 0.001 for CD206) (Fig.8A). IL-1β levels were in the low
physiological range and undetectable (data not shown), Ym1 was unaffected by MDG548.
Moreover, LPS increased TNF-α and IL-1β, and decreased CD206 secretion, leaving unaltered Ym1
levels. MDG548 reverted LPS effect on TNF-α and CD206 restoring physiological levels when
added 2 hours after LPS (p< 0.001 and p<0.005 VS LPS), while did not affect IL-1β and Ym1
levels (Fig.8B). When MDG548 was incubated at the same time point than LPS, only the effect on
CD206 was maintained.
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Fig.8. MDG548 modified the production of TNF-α and CD206 in MMGT12 cells. Cells were treated with
MDG548 at the doses of 10 μm and 50  μm (MDG10 and MDG50, respectively). TNF-α, CD206 and YM-1
were measured by ELISA increased in the group MDG548 at the dose of 10 μm (Fig. 8A). Cells were treated
with LPS in association with MDG548 10 μm 2 hrs later (s) or at the same time point (c). (*p< 0.05 for
TNF-α; p<0.001 for CD206) (Fig.8B).
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MDG548 affected phagocytosis in MMGT12 cells.
Qualitative evaluation of IR in MMGT12 cells showed that LPS slightly increased CD68 IR, while
MDG548 at the dose of 10 μm dramatically enhanced CD68 IR, particularly when administered 2
hrs after LPS. 50 μm of MDG548 displayed a similar but attenuated effect as compared to the low
dose (Fig.9).
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2. Neuroprotective properties of MDG548 in MPTP models in mice
MDG548 reverted MPTPp-induced motor impairment.
MDG548 prevented motor impairment induced  by MPTPp treatment. MPTPp chronic treatment
induced a  significant  increase  on  the  number  of  errors  per  step as  compared with  vehicle  (by
Tukey's post-hoc test), in agreement with previous characterization of this protocol (Schintu et al.
2009a).  Combined  treatment  with  MDG548  in  the  last  part  of  the  MPTPp  treatment  totally
prevented the increase of errors induced by MPTPp treatment (p<0.05 by Tukey's post-hoc test). 
Fig. 10. MDG548 prevented MPTPp-induced motor deficits. Motor impairment was expressed as total step
errors measured by the beam walking test. Combined treatment with MDG548 plus MPTPp prevented the
increase of  total  errors.  *p<0.05  versus vehicle-treated mice,  by Tukey post-hoc test;  ^p<0.05 versus
MPTP10, by Tuckey post-hoc test (n= 5-10 per group).
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MDG548 prevented MPTP-induced degeneration of the SNc in the subacute MPTP protocol.
In the subacute MPTP treatment, stereological evaluation of TH-IR and Nissl staining showed a
reduction in the number of neurons in the SNc of MPTP-treated mice by about 50% as compared to
vehicle (p<0.001 by Tukey’s post hoc test) (Fig. 11A, B). The lowest MDG548 dose was chosen
based on a pilot study where we found that MDG548 at the dose of 0.5 mg/kg was ineffective on
MPTP-induced nigral  neurodegeneration.  Moreover,  in  vitro  assays  showed that  MDG548 was
more potent that the control compound rosiglitazone, which we have found to be neuroprotective at
10 mg/kg in vivo in several previous studies (Schintu et al., 2009b; Carta et al., 2011; Pisanu et al.,
2014). We therefore further narrowed dose selection for MDG548 by using rosiglitazone effective
dose as the highest tested dose. The administration of MDG548 to MPTP-treated mice inhibited the
dopaminergic degeneration to a similar extent at all tested doses of 2, 5 and 10 mg/kg, with no
significant differences from the vehicle group (Fig. 11A, B).
Fig.  11.  MDG548 prevented  dopaminergic  degeneration of  the  SNc in  the  subacute  MPTP protocol.
Representative  images  of  the  SNc  of  mice  treated  with  vehicle,  MPTP or  MPTP+MDG548  (2  mg/kg).
Magnification 20X (A). Total number of TH+ and Nissl-stained cells in the SNc, as measured by unbiased
stereological  analysis  (B).  **p<0.05  versus  vehicle-treated  mice,  by  Tukey’s  post  hoc  test  (n=4–5  per
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group).
MDG548 arrested MPTP-induced degeneration of the SNc in the chronic MPTPp protocol.
When tested in the chronic MPTPp protocol, MDG548 arrested dopaminergic neurodegeneration in
the SNc. Stereological evaluation showed a reduction in TH-positive cells in the SNc of MPTPp
chronically-treated mice as compared to vehicle (p < 0.01). Neurodegeneration was progressively
increased during the chronic MPTPp treatment, with a slight reduction in TH-positive cells after
three MPTP injections (MPTP3),  and a larger neuronal loss after subsequent injections (MPTP7,
MPTP10), in agreement with the previous characterization of this MPTPp protocol (Schintu et al.,
2009a).  The  repeated  administration  of  MDG548  starting  after  the  seventh  MPTPp  injection
(MPTP+MDG548) arrested the dopaminergic cell death, with no significant differences in number
of TH+ cells as compared to vehicle. Simultaneous administration of PPARγ antagonist GW9662
(MPTP + MDG548 + GW9662), counteracted the neuroprotective effect of the drug, with levels of
neuronal loss similar to MPTP10-treated rats (p< 0.05).
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Fig. 12. MDG548 arrested dopaminergic degeneration of the SNc in the chronic MPTPp protocol . Total
number of TH+ cells measured by stereological counting. Representative images of SNc in mice chronically
treated  with vehicle, MPTP or MPTP+MDG548 (magnification 20X). *p<0.05 versus vehicle-treated mice,
by Tukey post-hoc test; **p<0.01 versus vehicle-treated mice, by Tukey post-hoc test (n=5-10 per group).
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3. Modulation of the neuroinflammatory response by MDG548 in MPTP models
Changes in microglia activation and iNOS induction in the subacute MPTP protocol. 
Following subacute MPTP treatment, CD11b-IR was increased as compared to vehicle, in terms of
total IR area in the analysed region ( p<0.05 by Tukey’s post hoc test), as well as mean IR area/cell,
suggesting microglia proliferation and morphological changes respectively (p<0.05 by Tukey’s post
hoc  test).  Hence,  in  the  vehicle-treated  SNc  the  majority  of  microglia  displayed  a  resting
morphology with a small body, long and ramified processes, while after MPTP treatment microglia
was increased in number and displayed an activated morphology, characterized by a larger body
with  short  and  thicker  processes.  In  contrast,  after  MDG548/MPTP  co-treatment,  microglia
proliferation as well  as morphological changes were inhibited and cells  displayed a resting-like
morphology (Fig. 13). iNOS-positive cells were significantly increased by the MPTP treatment in
the SNc, while co-treatment with MDG548 attenuated the MPTP effect (p<0.05 by Tukey’s post
hoc test)  (Fig.  14).  As expected,  double IR confirmed that  iNOS immunostaining avoided TH-
positive neurons, suggesting that changes occurred in glial cells (Fig. 14). 
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Fig. 13. MDG548 inhibited microglia reactivity in the SNc. Representative images of CD11b+ cells in the
SNc of vehicle, MPTP and MPTP+MDG548 (5 mg/kg)-treated mice. Magnification 100X (A). CD11b in the
SNc was measured as the total area occupied by CD11b+ cells in the region of SNc analyzed (see text for
details) (B), and as the mean CD11b+ area/cell (C). *p<0.05 versus vehicle-treated mice by Tukey’s post hoc
test (n=4–5 per group).
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Fig. 14. MDG548 attenuated iNOS induction in the SNc. Representative images of iNOS+ cells in the SNc
of vehicle, MPTP and MPTP+MDG548 (5 mg/kg)-treated mice. Magnification 40X (A). iNOS+ cells were
automatically counted by Optimas image analyzer within a fixed area (see methods for details)  *p<0.05
versus vehicle-treated mice by Tukey’s post hoc test (n=4–5 per group).
63
Changes in microglia activation and cytokines production in the chronic MPTPp protocol. 
MDG548 attenuated microglia activation in the SNc. The MPTPp treatment produced a progressive
increase of reactive microglia. CD11b-IR was increased in MPTP7 and MPTP10-treated mice as
compared to vehicle, in terms of IR area/cell (p< 0.05 by Tukey's post-hoc test), as well as mean
total IR area in the analyzed region of SNc, suggesting microglial proliferation and morphological
changes,  respectively (p< 0.05 by Tukey's  post-hoc test).  After MPTPp+MDG548 co-treatment,
microglia activation was attenuated. 
IR for the pro-inflammatory cytokine TNF-α increased in microglia along with the chronic MPTPp
treatment (p< 0.05 by Tukey's post-hoc test). Co-administration of MDG548 in the last part of the
neurotoxin treatment reduced the levels of CD11b/TNF-α IR colocalization, reverting it to vehicle
values (p< 0.05 vs MPTP10 by Tukey's  post-hoc test).  Administration of the PPARγ antagonist
GW9662 reverted MDG548 effect (p< 0.05 vs veh by Tukey's post-hoc test).
IR for the anti-inflammatory cytokine CD206 in microglia decreased along with the chronic MPTPp
treatment,  reaching  50%  of  colocalization  in   CD11b(+)  cells  after  ten  MPTPp  injections,as
compared with vehicle (p< 0.05 vs veh by Tukey's post-hoc test). MDG548 reverted this trend,  by
reverting colocalization levels to vehicle values (p< 0.05 VS MPTP10 by Tukey's post-hoc test). 
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Fig.  14.  MDG548  decreased  MPTPp-induced  microglia  activation. CD11b  IR  was  measured  in  the
analyzed region of SNc as Cd11b+ mean area/cell (*p<0.05) and as total area occupied by Cd11b+ cells
(*p<0.05). Representative images of Cd11b+ cells in SNc of mice chronically treated with vehicle, MPTP
and MPTP+MDG548 (magnification 100X).
65
Fig.  15.  MDG548  inhibited  the  MPTPp-induced  production  of  TNF-α  in  microglia.  Representative
confocal  images  showing  colocalized  elements  (yellow)  in  CD11b  (red)  positive  cells  in  the  SNc  (A).
Percentage of colocalization of TNF-α IR in CD11b positive cells. *p<0.05  versus vehicle-treated mice, by
Tukey post-hoc test; ^p<0.05 versus MPTP10, by Tuckey post-hoc test (n= 5-10 per group) (B). 
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Fig. 16. MDG548 increased CD206 IR in microglia. Representative confocal images showing colocalized
elements (yellow) in CD11b (red) positive cells  in the  SNc (A).  Measure is  expressed as  percentage of
colocalization of CD206 IR in CD11b(+) cells (B). *p<0.05  VS vehicle-treated mice, by Tukey post-hoc test;
^p<0.05 vs MPTP 10, by Tuckey post-hoc test (n= 5-10 per group). 
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DISCUSSION
The present  study investigated  the neuroprotective properties  of  the  novel  non-TZD compound
MDG548, in relation with its ability to modulate the neuroinflammatory response in dopaminergic
areas. The whole study has been subdivided in three phases, where a dose-response study and the
potential neuroprotective efficacy of MDG548 were tested  in vitro  and  in vivo  in the first phase,
while  the  neuroprotective/disease  modifying  properties  and  immune-modulatory  activity  were
investigated in a clinically relevant  in vivo model of PD in a second set of experiments. Finally,
mechanisms of immunomodulation were investigated in more depth in cultured microglia cells.
Part of the data presented here, concerning results of the in vitro dose-response study and in vivo
testing of MDG548 in the subacute MPTP treatment, have been recently published in Neuroscience
(Lecca et al, 2015).
1. MDG548 is neuroprotective in PD models
Neuroprotective activity of MDG548 was first observed in vitro against H2O2 or MPP+ toxicity on
cultured neurons. Thereafter, neuroprotection was found in vivo in both the subacute and the chronic
MPTP mouse model of PD. 
1.1 In vitro studies
Cell viability assays showed a cytotoxic effect of MDG548 only at the higher concentration tested,
above 25 µM. Based on these data, a dose-range up to 10 µM was used in neuroprotection studies,
in  order  to  avoid  any  possible  confounding  cytotoxic  effects  of  MDG548  on  neuronal  cells.
Importantly,  MDG548  was  toxic  at  a  dose  range  equivalent  to  that  of  the  marketed  drug
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rosiglitazone,  a PPARγ agonist  extensively investigated for its  neuroprotective properties in PD
models. MDG548 effect against H2O2 insult in cultured neurons was assayed in order to evaluate
possible neuroprotective activity of the compound prior to in vivo testing. Results showed a dose-
dependent  protection  by  MDG548,  which  was  effective  in  preventing  and,  to  a  lesser  extent,
counteracting  the  H2O2-induced  cell  death,  when  administered  prior  or  together  with  the
neurotoxicant, respectively. As compared to rosiglitazone, MDG548 displayed a protective activity
against  H2O2 insult  at  lower  doses,  in  agreement  with  the  higher  PPARγ affinity  of  MDG548
reported  in  a  previous  study (Nevin  et  al.,  2012).  Relevant  to  subsequent  in  vivo experiments,
MDG548  was  neuroprotective  when  co-administered  with  MPP+  in  PC12  cells.  Moreover,
MDG548 protective effect was abolished by the specific PPARγ antagonist GW9662. Interestingly,
the  protective  effect  against  H2O2 required  a  24-h  pre-exposure to  MDG548.  Multiple  PPARγ-
mediated  mechanisms,  either  direct  and  indirect,  have  been  indicated  to  contribute  to  the
neuroprotective  efficacy  (Zhao  et  al.,  2015).  These  include  not  only  direct  post-translational
mechanisms such as PPARγ inhibitory binding to transcription factor NF-kB, but also modulation
of  the  expression  of  genes  involved  in  oxidative  stress  pathways  such  as  antioxidant  enzyme
catalase, a mechanism which may require drug pre-exposure. This last mechanism, by increasing
the  H2O2 buffering  capacity  of  neurons,  may  be  the  prevalent  mechanism for  neuroprotection
against acute H2O2 insult in the present study. 
1.2 In vivo   treatments
In vivo, neuroprotection was tested in two classical mouse models of dopaminergic degeneration
induced by MPTP administration (Carta et al., 2009). 
Firstly, a subacute MPTP model consisting in 4 injections once a day for 4 consecutive days, at the
dose of 20 mg/kg, was used. This protocol is suitable for a preliminary and rapid screening of novel
69
potentially neuroprotective compounds (Vila et al., 2000; Carta et al., 2009; Blesa et al., 2012). 
In a  second set  of  experiments,  the neuroprotective effect  of  MDG548 was investigated in  the
chronic  MPTPp model.  The MPTPp model  reproduces  several  features  of  PD,  particularly the
progressive nature of dopaminergic degeneration,  associated with a slow development of motor
impairment, which makes testing of drugs in this model clinically relevant (Petroske et al., 2001;
Carta et al., 2011). The progressive nature of this model allowed us to test MDG548 in presence of
a partial and ongoing degeneration of nigrostriatal neurons, reproducing more closely the disease
stage of parkinsonian patients at the moment of diagnosis. Moreover, in the MPTPp chronic model,
neuroinflammatory responses display a dynamic development as the neurodegeneration progresses,
offering  the  possibility  to  investigate  changes  in  neuroinflammation  related  with  the  different
disease stages (Pisanu et al, 2014).
In the subacute and chronic MPTP models, MDG548 administration was effective in preventing the
neurotoxin-induced neurodegeneration, as shown by the stereological counting of both TH-positive
and Nissl-positive cells in the SNc. Moreover, the neuroprotective effect was observed 4 days after
the  last  administration,  indicating  that  MPTP-induced  degeneration  was  actually  inhibited  by
MDG548 rather than simply delayed. 
Using this subacute protocol, MDG548 did not display a concentration-dependent response since all
tested doses 2, 5 and 10 mg/kg induced a comparable neuroprotective effect, suggesting that the
lowest dose was already fully effective. On the other hand, in a pilot experiment we found 0.5
mg/kg of MDG548 ineffective (data not shown). Since the in vitro assay allowed to test a broader
range of doses in order to obtain a concentration-dependent response, we can assume that a fine
tuning down of the dose-range in vivo would provide a similar response pattern. 
In the chronic MPTPp protocol, we used the lowest effective dose of MDG548, 2 mg/kg, tested in
the  previous  experiment.  As  previously  shown,  MPTPp-mediated  nigral  neurodegeneration
gradually  increased  at  progressive  time-points  along  the  neurotoxin  treatment.  We  found  that
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MDG548  arrested  the  neurodegenerative  process  when  tested  in  the  last  part  of  the  MPTPp
treatment,  in  presence  of  a  partial  and  ongoing  degeneration,  suggesting  a  disease-modifying
property of this drug.
Confirming  previous  studies,  the  chronic  MPTPp  intoxication  induced  motor  deficits  which
increased along with nigral degeneration (Meredith et al., 2008; Petroske et al., 2001; Schintu et al.,
2009a). By using the beam-walking test, a highly sensitive test for motor deficits in rodents, we
found that MDG548 completely prevented the development of MPTPp-induced motor impairment,
suggesting that neuroprotection was reflected by the recovery of motor function (Fleming et al.,
2004).
The selective PPARγ antagonist GW9662 counteracted MDG548-mediated neuroprotection. Recent
studies  reporting  in  vivo neuroprotection  by  non-selective  PPAR  agonists  have  suggested  that
different PPAR subtypes may be involved in this effect (Sadeghian et al., 2012; Swanson et al.,
2013).   MDG548 has potent  and highly selective PPARγ  agonist  activity,  therefore the present
results  strongly  support  the  primary  role  of  a  PPARγ-dependent  mechanism as  a  mediator  of
neuroprotection. (Nevin et al., 2012). Studies with TZDs compounds have suggested that receptor-
independent mechanisms might be involved in neuroprotection, such as binding to mitochondrial
protein mitoNEET, generating some doubt on the actual involvement of PPARγ in neuroprotection
(Feinstein  et al., 2005; Hunter et al., 2008). Although additional mechanisms cannot be excluded at
this  stage,  our  results  provide  evidence  that  specifically  targeting  PPARγ  is  sufficient  to  elicit
neuroprotection in the PD models used here.  The recent finding that dopaminergic neurons not
expressing PPARγ appears more susceptible to MPTP neurotoxicity supports our results (Swanson
and Emborg, 2014).
In previous studies we reported the neuroprotective efficacy of the TZD rosiglitazone in the same
chronic  MPTPp  mouse  model  of  PD  used  here  (Schintu  et  al.,  2009;  Carta  et  al.,  2011).
Rosiglitazone showed neuroprotective properties at the lowest effective dose of 10 mg/kg i.p., while
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lower doses such as 5 mg/kg were without an effect in that model (unpublished data).  Therefore, in
line with the in vitro results and along with the higher provisional blood brain barrier permeability
displayed by MDG548, the present data suggest an increased in vivo potency of MDG548 against
MPTP neurotoxicity as compared to rosiglitazone (Nevin et al., 2012).  
Recently,  concerns  have  been  raised  regarding  TZDs  rosiglitazone  and  pioglitazone  safety  in
diabetic patients, including increased bladder cancer risk and cardiovascular complications (Home
et al., 2009; Barbalat et al., 2012; Carta and Simuni, 2015). However, specifically designed studies
have suggested that unwanted side effects of TZDs may be largely due to off-target binding and
receptor-independent mechanisms (Cohen, 2005; Tseng and Tseng, 2012). These concerns, while
lessening the enthusiasm for supporting research on neuroprotection by TZDs in CNS pathologies,
has  prompted  for  search  of  alternative  non-TZDs  PPARγ  agonists  specifically  designed  for
neurodegenerative pathologies. MDG548 was specifically selected for this purpose from a broad
spectrum of potentially active non-TZDs compounds. The potent and selective PPARγ activity of
MDG548, by allowing the use of low doses to reach neuroprotection, may attenuate the risk of
untoward side effects. 
2. MDG548 displays immunomodulatory effects in microglia and in PD models in vivo.
2.1 Immunomodulatory effects in cultured microglia
Neuroinflammation  is  a  key  pathological  event  in  the  pathogenesis  of  PD.  A  chronic  and
dysregulated glial  response is  believed to contribute to the progression and spreading of nigral
degeneration mainly by an excessive release of inflammatory cytokines and neurotoxic species such
as reactive oxygen/nitrogen species,  free radicals,  iNOS induction,  which confer to  microglia a
72
toxic phenotype responsible for secondary damage to neighbouring neurons (Ramsey and Tansey,
2014). Therefore, targeting microglial response is considered a valuable strategy to modify disease
progression (Nolan et al., 2013). PPARγ, being highly expressed in immune cells throughout the
body including microglia, holds a pivotal role in the regulation of inflammatory responses mainly
by the regulation of the activity of NF-kB transcription factor (Moraes et  al.,  2006; Straus and
Glass,  2007),  and  several  evidence  have  suggested  that  the  regulation  of  neuroinflammatory
responses may represent a main mechanism of neuroprotection by PPARγ agonists (Dehmer et al.,
2004; Sundararajan et al., 2006; Pisanu et al., 2014). 
Many of the proven immunomodulatory effects of PPARγ are mediated by innate immune cells,
such as macrophages and monocytes  (Reddy,  2008). In turn, these cells produce a number of
PPARγ ligands,  which  can  potentiate  the  anti-inflammatory and proresolving properties  of  this
receptor on other immune cells. Importantly, targeting PPARγ is known to modulate the phenotype
of peripheral macrophages.  Hence,  a number of studies have shown that PPARγ modulates the
production  of  both  pro-  and  anti-inflammatory  cytokines  by  these  cells,  boosting  the  anti-
inflammatory benefit while suppressing the harmful macrophage phenotype (Odegaard et al., 2007).
We therefore hypothesized that the same role was carried by PPARγ expressed in microglia, were
they  may  boost  the  “alternatively”  activated  M2  phenotype,  that  is  associated  with  anti-
inflammatory characteristics and is  involved in the resolution phase of inflammation and in tissue
repair (Croasdell et al., 2015). 
We  first  investigated  the  effect  of  MDG548  in  a  classical  inflammatory  model  such  as  LPS
stimulation of  cultured HEK-Blue-hTLR4 cells  and found a dose-dependent  inhibition of LPS-
induced NF-kB activation. These results provided first evidence for an anti-inflammatory activity of
MDG548. PPARγ may inactivate NF-kB by direct binding to p50 and p65 subunits (Rossi et al.,
2000; Straus et al., 2000). In addition, it can induce an indirect NF-kB inhibition through several
mechanisms including upregulation of inhibitor kappa B (IkB) protein or activation of transcription
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factor Nrf2, which reduces NF-kB activation by dampening the oxidative load in the cell (Nolte et
al., 1998; Delerive et al., 2000; Shih et al., 2005). Interestingly, unlike the neuroprotective activity
in neurons, PPARγ  antagonist was unable to counteract NF-kB inhibition by MDG548 in HEK-
BluehTLR4 cells. Although additional studies will be needed to elucidate this result, which may be
related to the experimental setting and the cell line used in the assay, it should be noticed that NF-
kB was significantly inhibited at  concentrations  higher  than those required for  neuroprotection,
suggesting that additional uninvestigated mechanisms may be recruited for a full NF-kB inhibition
in TLR4 cells. 
To  investigate  the  immunomodulatory  function  of  MDG548,  we  designed  a  series  of  in  vitro
experiments were the effect of MDG548 was investigated in  pure cultured microglial  cells.  As
compared to the complex in vivo system, where the diffuse PPARγ expression in different cell types
does not allow to discriminate their function in selected cell population, the  in vitro experiments
allowed us to define the direct effect of PPARγ stimulation on microglia.  MMGT12 cells were
exposed to MDG548 in presence of the typical pro-inflammatory stimulus LPS and levels of pro-
inflammatory and anti-inflammatory markers in the exposure media from these cells were measured
by ELISA (Briers et al., 1994; Michelucci et al., 2009; Heurtaux et al., 2010). In particular, we
assessed, after exposure to MDG548, the concentration of the pro-inflammatory cytokine TNF-α,
and of the surface markers CD206 (mannose receptor) and Ym1, which are typically expressed by
alternatively activated microglia. Moreover, we assessed the expression of the phagocytosis marker
CD68  by  immunocytochemistry.  At  the  lowest  dose  tested,  MDG548  decreased  TNF-α  and
dramatically increased CD206 levels in untreated cells. A not significant or attenuated effect was
observed with the highest dose tested, in line with the cytotoxic effect observed with this dose in
cultured  neurons  (see  above).  Ym1  was  not  modulated  by  MDG548  at  any  tested  dose.
Furthermore, in LPS activated microglia MDG548 restored TNF-α and CD206 to vehicle values
reverting the LPS effect. All these effects were more marked when MDG548 was added 2 hrs after
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LPS stimulation, suggesting that the drug was most effective in activated microglia. 
It is worth to notice the strong effect of MDG548 on CD206 levels, suggesting a main role of this
protein  in  PPARγ-mediated  effects.  CD206,  or  the  mannose  receptor, is  a  pattern-recognition
receptor involved in innate and adaptive immunity. In the brain the mannose receptor expressed by
microglia  mediates  phagocytosis  by  these  cells,  and  is  regulated  by  various  cytokines,  being
downregulated  by  pro-inflammatory  cytokines  and  upregulated  by  anti-inflammatory  cytokines
(Régnier-Vigouroux,  2003;  Zimmer  et  al,  2003).  Accordingly,  we  found  that  CD68
immunoreactivity was increased by LPS, and further highly enhanced by the PPARγ agonist.  
In  contrast,  Ym1  levels  did  not  display  any  significant  modification  after  MDG548  addition.
Although Ym1 is a well-known marker of M2 macrophage a possible functional relation between
PPARγ  and  Ym1  is  still  elusive  and  poorly  investigated  (Rőszer,  2015).  Recent  studies  have
clarified that microglia activation is a complex and dynamic process, depending on the type and
intensity of the stimulus, which may lead to variable activation profiles. Based on this recent view,
microglia  activation  cannot  be  simplified  in  M1 or  M2 states,  but  there  are  many degrees  of
activation, especially when considering the complexity of an in vivo environment. The results of the
present study show that stimulation of microglial PPARγ enhances the anti-inflammatory profile of
these cells, together with the phagocytic activity, while suppressing the pro-inflammatory profile of
activation. A number of studies have suggested that prevalence of anti-inflammatory microglia and
enhanced phagocytic activity of these cells may sustain the deleterious neuroinflammatory response
in PD, which contribute to the progression of neurodegeneration (Sanchez-Guajardo et al., 2010).
Here,  we  propose  that  the  phagocytic  activity  of  microglia,  sustained  by  increased  CD206
expression,  may hold  a  positive  function  when associated  with  an  enhanced anti-inflammatory
profile, and contribute to PPARγ-mediated neuroprotection.
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2.2 Immunomodulatory effects in in vivo   treatments
In vivo studies confirmed the observations made in cultured microglia. In both subacute and chronic
MPTP protocols, MDG548 reduced MPTP-induced microglia reactivity, as shown by CD11b IR,
both in terms of proliferation and changes in cell morphology. Based on Kreutzberg classification,
vehicle-  treated  mice  showed  a  stage  of  resting  microglia,  whereas  after  MPTP treatment  a
progressive  increase  of  microglia  activation  has  been  clearly  observed.  When  MDG548  was
administrated (in co-administration with MPTP in subacute protocol, and after the seventh MPTPp
injection  in  chronic  protocol),  morphological  changes  typical  of  activation  processes  were
attenuated. 
Moreover, in the subacute MPTP protocol MDG548 significantly attenuated MPTP-induced iNOS
expression. In chronic MPTPp treatment, MDG548 decreased TNF-α IR while  increasing  CD206
levels, in accordance with the in vitro studies on cultured microglia. 
In line with this result, previous studies showed the inhibitory activity of PPARγ agonists TZDs on
NF-kB activity both in vitro and in in vivo models of PD (Dehmer et al., 2004; Moraes et al., 2006).
Pioglitazone administration in a rodent PD model induced the expression of the inhibitory protein
(I)-kB and the consequent inhibition of NF-kB activity, by blocking subunit p65 translocation into
the nucleus (Dehmer et al., 2004).  Moreover, TZDs have been shown to either reduce microglia
activation and/or modify the microglial response in terms of cytokine production, both in rodent and
primate models of PD (Cunard et al., 2002; Luna-Medina et al., 2005; Schintu et al., 2009; Ji et al.,
2010; Swanson et al., 2011; Pisanu et al., 2014). Furthermore, previous studies have shown that
PPARγ  agonists inhibited LPS-induced iNOS expression both in vitro and  in vivo models of PD
(Kitamura et al., 1999; Hunter et al., 2007). 
Among pro-inflammatory cytokines,  TNF-α plays a pivotal role in neuroinflammatory response,
and it has been functionally related to neurodegeneration in several disorders including PD, in many
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experimental models. Moreover, an increase in its production has been observed in several studies
of MPTP-induced neurotoxicity (Lofrumento et al., 2011; Luchtman et al., 2009); as confirm of
these data, a deficiency in TNF receptors has been showed to inhibit microglial activation and to
protect  dopaminergic  neurons  against  MPTP  neurotoxicity  (Sriram  et  al.,  2006),  while  TNF
administration elicit nigral degeneration (De Lella Ezcurra et al., 2010). TNF-α may induce NF-kB
nuclear  translocation  via  stimulating  proteolytic  degradation  of  inhibitory  protein  (I)-kB  and
activating apoptotic processes, in dopaminergic neurons (Wajant et al., 2003).
Targeting microglia activation in order to stimulate an alternative anti-inflammatory phenotype has
been proposed as a possible strategy for neuroprotective approaches in AD (Hoozemans et al., 2006;
Jankowsky et al., 2003). Moreover, an aberrant microglia polarization has been observed in LPS-
treated mice and in the aged brain,  suggesting that it  may represent a damaging mechanism in
neurodegenerative diseases and in ageing processes (Lund et al., 2006; Jimenez et al., 2008; Nolan
et al.,  2005).  We propose that  targeting microglia  polarization by PPARγ agonists  may provide
neuroprotection  by  switching  the  aberrant  microglia  polarization  observed  in  PD  in  an  anti-
inflammatory profile. Phagocytosis has been regarded as a deleterious mechanism in the PD brain,
which may contribute to neurons destruction. We believe that enhancing the phagocytic activity of
microglia  while  boosting  an  anti-inflammatory  profile  may  help  the  restorative  process  by
improving the scavenging process of debris or perhaps toxic forms of proteins. 
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CONCLUSIONS
MDG548 is  a  potent  and  selective  PPARγ agonist,  displaying  higher  receptor  affinity  for  this
receptor,  compared  with  currently  employed  TZDs.  MDG548  showed  neuroprotective  and
immunomodulatory properties in  in vitro as well as  in vivo models of PD, at  lower doses than
TZDs. Such increased potency, together with the non-TZD structure of the compound, may reduce
the risk of untoward side-effects related to use of excessive doses and/or to receptor-independent
mechanisms. Results suggest that MDG548 exerts an immunomodulatory action via a modulation
of microglia polarization correcting the imbalance between pro- over anti-inflammatory molecules,
offering a novel immunomodulatory approach to neuroprotection in PD.
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